#BEGIN_DRUGCARD DB04522

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C3H8NO6P

# Chemical_IUPAC_Name:
(2S)-2-amino-3-(phosphonooxy)propanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
The phosphoric acid ester of serine. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Phosphonoserine

# HET_ID:
SEP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C3H8NO6P/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1

# InChI_Key:
InChIKey=BZQFBWGGLXLEPQ-REOHCLBHSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4522

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
185.0725

# Molecular_Weight_Mono:
185.008923505

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1SZM

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.3

# Predicted_LogS:
-0.97

# Predicted_Water_Solubility:
1.99e+01 g/l

# Primary_Accession_No:
DB04522

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
68841

# PubChem_Substance_ID:
46505297

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02883

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H](COP(O)(O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:25 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
REG1A

# Drug_Target_10_GenBank_ID_Gene:
M27190

# Drug_Target_10_GenBank_ID_Protein:
623413

# Drug_Target_10_GeneCard_ID:
REG1A

# Drug_Target_10_Gene_Name:
REG1A

# Drug_Target_10_Gene_Sequence:
>501 bp
ATGGCTCAGACCAACTCGTTCTTCATGCTGATCTCCTCCCTGATGTTCCTGTCTCTGAGC
CAAGGCCAAGAGGCCCAGACAGAGTTGCCCCAGGCCCGGATCAGCTGCCCAGAAGGCACC
AATGCCTATCGCTCCTACTGCTACTACTTTAATGAAGACCGTGAGACCTGGGTTGATGCA
GATCTCTATTGCCAGAACATGAATTCGGGCAACCTGGTGTCTGTGCTCACCCAGGCCGAG
GGTGCCTTTGTGGCCTCACTGATTAAGGAGAGTGGCACTGATGACTTCAATGTCTGGATT
GGCCTCCATGACCCCAAAAAGAACCGCCGCTGGCACTGGAGCAGTGGGTCCCTGGTCTCC
TACAAGTCCTGGGGCATTGGAGCCCCAAGCAGTGTTAATCCTGGCTACTGTGTGAGCCTG
ACCTCAAGCACAGGATTCCAGAAATGGAAGGATGTGCCTTGTGAAGACAAGTTCTCCTTT
GTATGCAAGTTCAAAAACTAG

# Drug_Target_10_General_Function:
Involved in sugar binding

# Drug_Target_10_General_References:
10625646	Gerbaud V, Pignol D, Loret E, Bertrand JA, Berland Y, Fontecilla-Camps JC, Canselier JP, Gabas N, Verdier JM: Mechanism of calcite crystal growth inhibition by the N-terminal undecapeptide of lithostathine. J Biol Chem. 2000 Jan 14;275(2):1057-64.
2226837	Itoh T, Tsuzuki H, Katoh T, Teraoka H, Matsumoto K, Yoshida N, Terazono K, Watanabe T, Yonekura H, Yamamoto H, et al.: Isolation and characterization of human reg protein produced in Saccharomyces cerevisiae. FEBS Lett. 1990 Oct 15;272(1-2):85-8.
2332435	Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H: Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. J Biol Chem. 1990 May 5;265(13):7432-9.
2394826	de la Monte SM, Ozturk M, Wands JR: Enhanced expression of an exocrine pancreatic protein in Alzheimer's disease and the developing human brain. J Clin Invest. 1990 Sep;86(3):1004-13.
2493268	De Caro AM, Adrich Z, Fournet B, Capon C, Bonicel JJ, De Caro JD, Rovery M: N-terminal sequence extension in the glycosylated forms of human pancreatic stone protein. The 5-oxoproline N-terminal chain is O-glycosylated on the 5th amino acid residue. Biochim Biophys Acta. 1989 Feb 23;994(3):281-4.
2525567	Giorgi D, Bernard JP, Rouquier S, Iovanna J, Sarles H, Dagorn JC: Secretory pancreatic stone protein messenger RNA. Nucleotide sequence and expression in chronic calcifying pancreatitis. J Clin Invest. 1989 Jul;84(1):100-6.
2764894	Stewart TA: The human reg gene encodes pancreatic stone protein. Biochem J. 1989 Jun 1;260(2):622-3.
2963000	Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, Okamoto H: A novel gene activated in regenerating islets. J Biol Chem. 1988 Feb 15;263(5):2111-4.
3108036	Rouimi P, Bonicel J, Rovery M, De Caro A: Cleavage of the Arg-Ile bond in the native polypeptide chain of human pancreatic stone protein. FEBS Lett. 1987 Jun 1;216(2):195-9.
3541906	Montalto G, Bonicel J, Multigner L, Rovery M, Sarles H, De Caro A: Partial amino acid sequence of human pancreatic stone protein, a novel pancreatic secretory protein. Biochem J. 1986 Aug 15;238(1):227-32.
3665916	De Caro AM, Bonicel JJ, Rouimi P, De Caro JD, Sarles H, Rovery M: Complete amino acid sequence of an immunoreactive form of human pancreatic stone protein isolated from pancreatic juice. Eur J Biochem. 1987 Oct 1;168(1):201-7.
3908481	Gross J, Carlson RI, Brauer AW, Margolies MN, Warshaw AL, Wands JR: Isolation, characterization, and distribution of an unusual pancreatic human secretory protein. J Clin Invest. 1985 Dec;76(6):2115-26.
8654365	Bertrand JA, Pignol D, Bernard JP, Verdier JM, Dagorn JC, Fontecilla-Camps JC: Crystal structure of human lithostathine, the pancreatic inhibitor of stone formation. EMBO J. 1996 Jun 3;15(11):2678-84.
8961348	Patard L, Stoven V, Gharib B, Bontems F, Lallemand JY, De Reggi M: What function for human lithostathine?: structural investigations by three-dimensional structure modeling and high-resolution NMR spectroscopy. Protein Eng. 1996 Nov;9(11):949-57.

# Drug_Target_10_HGNC_ID:
HGNC:9951

# Drug_Target_10_HPRD_ID:
01338

# Drug_Target_10_ID:
1130

# Drug_Target_10_Locus:
2p12

# Drug_Target_10_Molecular_Weight:
18731

# Drug_Target_10_Name:
Lithostathine 1 alpha

# Drug_Target_10_Number_of_Residues:
166

# Drug_Target_10_PDB_ID:
1LIT

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00059	Lectin_C

# Drug_Target_10_Protein_Sequence:
>Lithostathine 1 alpha precursor
MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA
DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS
YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
1-22

# Drug_Target_10_Specific_Function:
Might act as an inhibitor of spontaneous calcium carbonate precipitation. May be associated with neuronal sprouting in brain, and with brain and pancreas regeneration

# Drug_Target_10_SwissProt_ID:
P05451

# Drug_Target_10_SwissProt_Name:
REG1A_HUMAN

# Drug_Target_10_Synonyms:
ICRF
Islet cells regeneration factor
Islet of Langerhans regenerating protein
Lithostathine 1 alpha precursor
PSP
PTP
Pancreatic stone protein
Pancreatic thread protein
REG
Regenerating protein I alpha

# Drug_Target_10_Theoretical_pI:
5.73

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
Not Available

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
SMAD2

# Drug_Target_11_Gene_Sequence:
Not Available

# Drug_Target_11_General_Function:
Not Available

# Drug_Target_11_General_References:
Not Available

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
6955

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
Not Available

# Drug_Target_11_Name:
Mothers against decapentaplegic homolog 2

# Drug_Target_11_Number_of_Residues:
0

# Drug_Target_11_PDB_ID:
Not Available

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
Not Available

# Drug_Target_11_Protein_Sequence:
Not Available

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
Not Available

# Drug_Target_11_Specific_Function:
Not Available

# Drug_Target_11_SwissProt_ID:
Q15796

# Drug_Target_11_SwissProt_Name:
SMAD2_HUMAN

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
Not Available

# Drug_Target_11_Transmembrane_Regions:
Not Available

# Drug_Target_12_Cellular_Location:
Cytoplasmic

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
Not Available

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
AB006424

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
glsA1

# Drug_Target_12_Gene_Sequence:
>984 bp
TTAAAAAATGCTGAGCTCCCATTCCTGCGCCATATGCTTCAGCAGCATACCGCCAGTGAG
GCTGTTGCCGTATTCATCAATGGCAGGCCCGTAAATGCCGATGCCGCATCCGGATTGAAA
AGGCTGTTCTCTTCTGGCGCTTGGAGGCACCAGCGCCATGATGCCGCCGGAGACGCCGCT
TTTGGCCGGCACGCCGACAAACGCCGCATATTTGCCTGAAGCGTTGTACATGCCGCACGT
CAGCATTAATGCCTTGGCCAATTTTGCCACATCTTTTGGAATCACCTGCTCGTGTCGAAT
CGGATGATACCCGTCATGAGCAAGGATCAGGCCGATCAACGCAATATCTTCTGTAGTGCT
CTCCATAGCGCATTGCTTCAAGTACACCTCAAGTGTTTCTTCTACTTCAGCTTCTAAAAA
GTTTGTTTCTTTTAAATAGTAGGCCAGCGCTCTGTTGCGGTGGGCGGTTTCCCATTCAGA
ACGGAATACTTCTTCATGAATTCTTGGCCGTTTTCCTATCAAAGTTTCCATCACCGAGTA
AAGAAACTCGAGCTTTTCGTATGCAGATTCTCCGGGAAGGATCGAAGCGATGGTGAGGGC
ACCCGCGTTGATCATGGGATTGAAGGGCTTTCCCGGCTTGTTGATTTCGAGCCGAATGAT
TGAATTAAAGGCGTCACCTGTCGGCTCGACATCTACGCGGTCAAGCACATAGGGAATGCC
GCGGCTCATGCAGGCGGCAATAAAGCTAATCACTTTTGAAATGCTTTGCATGGTAAAAGA
GACGTTCCAGTCGCCGGCGTGTATCATCGTTCCATCAGGCTCCAATACACAGATGCCGAG
CTGTGAATCATTGACTTTTCCTAAAGCGGGGATATAGTTTGCGCTTTGTCCATTGGCGGC
AAAAGGGCGATAGTATTCAACCCAATCATGAAGCTGTAACGCCGGGTTTATGTCTTTCTG
GTGCTCTTTTATCAATTCTTTCAT

# Drug_Target_12_General_Function:
Involved in glutaminase activity

# Drug_Target_12_General_References:
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
4542

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
36187

# Drug_Target_12_Name:
Glutaminase 1

# Drug_Target_12_Number_of_Residues:
327

# Drug_Target_12_PDB_ID:
1MKI

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF04960	Glutaminase

# Drug_Target_12_Protein_Sequence:
>Glutaminase 1
MKELIKEHQKDINPALQLHDWVEYYRPFAANGQSANYIPALGKVNDSQLGICVLEPDGTM
IHAGDWNVSFTMQSISKVISFIAACMSRGIPYVLDRVDVEPTGDAFNSIIRLEINKPGKP
FNPMINAGALTIASILPGESAYEKLEFLYSVMETLIGKRPRIHEEVFRSEWETAHRNRAL
AYYLKETNFLEAEVEETLEVYLKQCAMESTTEDIALIGLILAHDGYHPIRHEQVIPKDVA
KLAKALMLTCGMYNASGKYAAFVGVPAKSGVSGGIMALVPPSARREQPFQSGCGIGIYGP
AIDEYGNSLTGGMLLKHMAQEWELSIF

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
L-glutamine + H(2)O = L-glutamate + NH(3)

# Drug_Target_12_SwissProt_ID:
O31465

# Drug_Target_12_SwissProt_Name:
GLSA1_BACSU

# Drug_Target_12_Synonyms:
EC 3.5.1.2

# Drug_Target_12_Theoretical_pI:
5.40

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
M64606

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
cysG

# Drug_Target_13_Gene_Sequence:
>1374 bp
GTGGACCATTTGCCTATATTTTGTCAATTACGCGACCGCGACTGTCTGATCGTCGGCGGT
GGCGATGTCGCAGAACGCAAAGCACGGTTACTGCTGGAAGCAGGCGCACGTTTAACGGTC
AATGCGCTAACCTTTATTCCACAGTTCACCGTATGGGCAAATGAAGGCATGTTGACTCTG
GTTGAGGGACCGTTCGACGAAACGCTTCTCGACTCGTGTTGGCTGGCGATCGCGGCCACT
GACGACGATACCGTCAACCAGCGCGTCAGCGACGCGGCGGAGTCACGCCGTATCTTTTGC
AACGTGGTGGATGCGCCGAAAGCCGCCAGCTTTATCATGCCCTCCATTATTGACCGCTCG
CCGCTGATGGTCGCCGTCTCCTCGGGCGGCACCTCCCCGGTGCTGGCGCGTCTGCTGCGC
GAGAAACTGGAATCGCTGCTGCCGCAGCATCTGGGGCAGGTCGCGCGCTATGCCGGGCAA
CTCCGCGCCCGAGTGAAAAAGCAGTTTGCCACGATGGGCGAGCGTCGTCGCTTCTGGGAA
AAATTTTTCGTCAATGACCGGCTGGCGCAGTCGCTGGCGAATGCCGATGAGAAAGCGGTT
AACGCGACAACCGAACGCCTGTTTAGCGAACCGCTGGATCACCGTGGCGAAGTCGTGCTG
GTCGGCGCCGGGCCGGGCGATGCCGGACTGCTGACGCTGAAAGGGTTACAACAAATCCAA
CAGGCGGATATCGTGGTTTACGATCGCCTCGTCTCCGACGACATTATGAACCTGGTACGC
CGCGATGCCGATCGGGTCTTTGTGGGGAAACGCGCGGGTTACCACTGCGTCCCACAGGAG
GAAATCAACCAGATCCTGCTGCGTGAAGCGCAAAAAGGTAAACGCGTGGTACGCCTGAAA
GGCGGCGATCCCTTTATCTTTGGTCGCGGCGGCGAAGAGCTGGAAACGCTGTGTCATGCC
GGTATTCCTTTCTCGGTAGTGCCGGGGATTACCGCGGCTTCCGGCTGCTCCGCCTACTCC
GGTATTCCGCTAACTCATCGCGATTACGCCCAGAGCGTACGTCTGGTCACGGGTCACCTG
AAAACCGGCGGCGAGCTGGACTGGGAAAACCTGGCGGCAGAAAAACAGACGCTGGTGTTC
TACATGGGGCTGAATCAGGCAGCGACTATCCAGGAAAAACTGATCGCATTCGGTATGCAG
GCCGATATGCCGGTTGCGCTGGTAGAAAACGGTACCTCCGTGAAGCAACGCGTCGTCCAC
GGTGTGCTGACGCAGCTCGGTGAATTAGCGCAACAGGTTGAAAGCCCGGCGCTGATTATC
GTTGGTCGCGTGGTAGCCTTACGCGATAAATTAAATTGGTTCTCTAATCATTAA

# Drug_Target_13_General_Function:
Involved in methyltransferase activity

# Drug_Target_13_General_References:
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.
1987123	Wu JY, Siegel LM, Kredich NM: High-level expression of Escherichia coli NADPH-sulfite reductase: requirement for a cloned cysG plasmid to overcome limiting siroheme cofactor. J Bacteriol. 1991 Jan;173(1):325-33.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4318

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
50147

# Drug_Target_13_Name:
Siroheme synthase

# Drug_Target_13_Number_of_Residues:
457

# Drug_Target_13_PDB_ID:
1PJT

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00590	TP_methylase

# Drug_Target_13_Protein_Sequence:
>Siroheme synthase
MDHLPIFCQLRDRDCLIVGGGDVAERKARLLLEAGARLTVNALTFIPQFTVWANEGMLTL
VEGPFDETLLDSCWLAIAATDDDTVNQRVSDAAESRRIFCNVVDAPKAASFIMPSIIDRS
PLMVAVSSGGTSPVLARLLREKLESLLPQHLGQVARYAGQLRARVKKQFATMGERRRFWE
KFFVNDRLAQSLANADEKAVNATTERLFSEPLDHRGEVVLVGAGPGDAGLLTLKGLQQIQ
QADIVVYDRLVSDDIMNLVRRDADRVFVGKRAGYHCVPQEEINQILLREAQKGKRVVRLK
GGDPFIFGRGGEELETLCHAGIPFSVVPGITAASGCSAYSGIPLTHRDYAQSVRLVTGHL
KTGGELDWENLAAEKQTLVFYMGLNQAATIQEKLIAFGMQADMPVALVENGTSVKQRVVH
GVLTQLGELAQQVESPALIIVGRVVALRDKLNWFSNH

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Multifunctional enzyme that catalyze the SAM-dependent methylation of uroporphyrinogen III at position C-2 and C-7 to form precorrin-2 and then position C-12 or C-18 to form trimethylpyrrocorphin 2. It also catalyzes the conversion of precorrin-2 into siroheme. This reaction consist of the NAD- dependent oxidation of precorrin-2 into sirohydrochlorin and its subsequent ferrochelation into siroheme

# Drug_Target_13_SwissProt_ID:
P25924

# Drug_Target_13_SwissProt_Name:
CYSG_SALTY

# Drug_Target_13_Synonyms:
Not Available

# Drug_Target_13_Theoretical_pI:
6.79

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Cytoplasm

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
Not Available

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
Z19137

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
ptsH

# Drug_Target_14_Gene_Sequence:
>267 bp
ATGGAAAAGAAAGAATTTCACATTGTAGCAGAAACAGGAATTCACGCACGTCCAGCTACT
TTATTAGTACAAACTGCAAGCAAATTTAACTCAGATATTAACTTAGAATACAAAGGTAAA
TCTGTTAACTTAAAATCAATCATGGGCGTTATGTCTTTAGGCGTTGGTCAAGGTTCTGAC
GTAACAATCACTGTTGATGGTGCTGACGAAGCTGAAGGAATGGCAGCAATCGTTGAAACA
TTACAAAAAGAAGGATTGGCTGAATAA

# Drug_Target_14_General_Function:
Involved in sugar:hydrogen ion symporter activity

# Drug_Target_14_General_References:
11054290	Audette GF, Engelmann R, Hengstenberg W, Deutscher J, Hayakawa K, Quail JW, Delbaere LT: The 1.9 A resolution structure of phospho-serine 46 HPr from Enterococcus faecalis. J Mol Biol. 2000 Nov 3;303(4):545-53.
11168402	Maurer T, Doker R, Gorler A, Hengstenberg W, Kalbitzer HR: Three-dimensional structure of the histidine-containing phosphocarrier protein (HPr) from Enterococcus faecalis in solution. Eur J Biochem. 2001 Feb;268(3):635-44.
12663927	Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR, Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT, Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J, Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM: Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science. 2003 Mar 28;299(5615):2071-4.
3098288	Deutscher J, Pevec B, Beyreuther K, Kiltz HH, Hengstenberg W: Streptococcal phosphoenolpyruvate-sugar phosphotransferase system: amino acid sequence and site of ATP-dependent phosphorylation of HPr. Biochemistry. 1986 Oct 21;25(21):6543-51.
8421502	Jia Z, Vandonselaar M, Quail JW, Delbaere LT: Active-centre torsion-angle strain revealed in 1.6 A-resolution structure of histidine-containing phosphocarrier protein. Nature. 1993 Jan 7;361(6407):94-7.
9523711	Hahmann M, Maurer T, Lorenz M, Hengstenberg W, Glaser S, Kalbitzer HR: Structural studies of histidine-containing phosphocarrier protein from Enterococcus faecalis. Eur J Biochem. 1998 Feb 15;252(1):51-8.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
5689

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
9321

# Drug_Target_14_Name:
Phosphocarrier protein HPr

# Drug_Target_14_Number_of_Residues:
88

# Drug_Target_14_PDB_ID:
1PTF

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00381	PTS-HPr

# Drug_Target_14_Protein_Sequence:
>Phosphocarrier protein HPr
MEKKEFHIVAETGIHARPATLLVQTASKFNSDINLEYKGKSVNLKSIMGVMSLGVGQGSD
VTITVDGADEAEGMAAIVETLQKEGLAE

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
P-Ser-HPr interacts with the catabolite control protein A (ccpA), forming a complex that binds to DNA at the catabolite response elements cre, operator sites preceding a large number of catabolite-regulated genes. Thus, P-Ser-HPr is a corepressor in carbon catabolite repression (CCR), a mechanism that allows bacteria to coordinate and optimize the utilization of available carbon sources. P-Ser-HPr also plays a role in inducer exclusion, in which it probably interacts with several non-PTS permeases and inhibits their transport activity (By similarity)

# Drug_Target_14_SwissProt_ID:
P07515

# Drug_Target_14_SwissProt_Name:
PTHP_ENTFA

# Drug_Target_14_Synonyms:
Histidine-containing protein

# Drug_Target_14_Theoretical_pI:
4.58

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
CFTR

# Drug_Target_15_GenBank_ID_Gene:
M28668

# Drug_Target_15_GenBank_ID_Protein:
180332

# Drug_Target_15_GeneCard_ID:
CFTR

# Drug_Target_15_Gene_Name:
CFTR

# Drug_Target_15_Gene_Sequence:
>4443 bp
ATGCAGAGGTCGCCTCTGGAAAAGGCCAGCGTTGTCTCCAAACTTTTTTTCAGCTGGACC
AGACCAATTTTGAGGAAAGGATACAGACAGCGCCTGGAATTGTCAGACATATACCAAATC
CCTTCTGTTGATTCTGCTGACAATCTATCTGAAAAATTGGAAAGAGAATGGGATAGAGAG
CTGGCTTCAAAGAAAAATCCTAAACTCATTAATGCCCTTCGGCGATGTTTTTTCTGGAGA
TTTATGTTCTATGGAATCTTTTTATATTTAGGGGAAGTCACCAAAGCAGTACAGCCTCTC
TTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAACGCTCTATCGCG
ATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCA
GCCATTTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATT
TATAAGAAGACTTTAAAGCTGTCAAGCCGTGTTCTAGATAAAATAAGTATTGGACAACTT
GTTAGTCTCCTTTCCAACAACCTGAACAAATTTGATGAAGGACTTGCATTGGCACATTTC
GTGTGGATCGCTCCTTTGCAAGTGGCACTCCTCATGGGGCTAATCTGGGAGTTGTTACAG
GCGTCTGCCTTCTGTGGACTTGGTTTCCTGATAGTCCTTGCCCTTTTTCAGGCTGGGCTA
GGGAGAATGATGATGAAGTACAGAGATCAGAGAGCTGGGAAGATCAGTGAAAGACTTGTG
ATTACCTCAGAAATGATTGAAAATATCCAATCTGTTAAGGCATACTGCTGGGAAGAAGCA
ATGGAAAAAATGATTGAAAACTTAAGACAAACAGAACTGAAACTGACTCGGAAGGCAGCC
TATGTGAGATACTTCAATAGCTCAGCCTTCTTCTTCTCAGGGTTCTTTGTGGTGTTTTTA
TCTGTGCTTCCCTATGCACTAATCAAAGGAATCATCCTCCGGAAAATATTCACCACCATC
TCATTCTGCATTGTTCTGCGCATGGCGGTCACTCGGCAATTTCCCTGGGCTGTACAAACA
TGGTATGACTCTCTTGGAGCAATAAACAAAATACAGGATTTCTTACAAAAGCAAGAATAT
AAGACATTGGAATATAACTTAACGACTACAGAAGTAGTGATGGAGAATGTAACAGCCTTC
TGGGAGGAGGGATTTGGGGAATTATTTGAGAAAGCAAAACAAAACAATAACAATAGAAAA
ACTTCTAATGGTGATGACAGCCTCTTCTTCAGTAATTTCTCACTTCTTGGTACTCCTGTC
CTGAAAGATATTAATTTCAAGATAGAAAGAGGACAGTTGTTGGCGGTTGCTGGATCCACT
GGAGCAGGCAAGACTTCACTTCTAATGATGATTATGGGAGAACTGGAGCCTTCAGAGGGT
AAAATTAAGCACAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGC
ACCATTAAAGAAAATATCATCTTTGGTGTTTCCTATGATGAATATAGATACAGAAGCGTC
ATCAAAGCATGCCAACTAGAAGAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTT
CTTGGAGAAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGA
GCAGTATACAAAGATGCTGATTTGTATTTATTAGACTCTCCTTTTGGATACCTAGATGTT
TTAACAGAAAAAGAAATATTTGAAAGCTGTGTCTGTAAACTGATGGCTAACAAAACTAGG
ATTTTGGTCACTTCTAAAATGGAACATTTAAAGAAAGCTGACAAAATATTAATTTTGAAT
GAAGGTAGCAGCTATTTTTATGGGACATTTTCAGAACTCCAAAATCTACAGCCAGACTTT
AGCTCAAAACTCATGGGATGTGATTCTTTCGACCAATTTAGTGCAGAAAGAAGAAATTCA
ATCCTAACTGAGACCTTACACCGTTTCTCATTAGAAGGAGATGCTCCTGTCTCCTGGACA
GAAACAAAAAAACAATCTTTTAAACAGACTGGAGAGTTTGGGGAAAAAAGGAAGAATTCT
ATTCTCAATCCAATCAACTCTATACGAAAATTTTCCATTGTGCAAAAGACTCCCTTACAA
ATGAATGGCATCGAAGAGGATTCTGATGAGCCTTTAGAGAGAAGGCTGTCCTTAGTACCA
GATTCTGAGCAGGGAGAGGCGATACTGCCTCGCATCAGCGTGATCAGCACTGGCCCCACG
CTTCAGGCACGAAGGAGGCAGTCTGTCCTGAACCTGATGACACACTCAGTTAACCAAGGT
CAGAACATTCACCGAAAGACAACAGCATCCACACGAAAAGTGTCACTGGCCCCTCAGGCA
AACTTGACTGAACTGGATATATATTCAAGAAGGTTATCTCAAGAAACTGGCTTGGAAATA
AGTGAAGAAATTAACGAAGAAGACTTAAAGGAGTGCCTTTTTGATGATATGGAGAGCATA
CCAGCAGTGACTACATGGAACACATACCTTCGATATATTACTGTCCACAAGAGCTTAATT
TTTGTGCTAATTTGGTGCTTAGTAATTTTTCTGGCAGAGGTGGCTGCTTCTTTGGTTGTG
CTGTGGCTCCTTGGAAACACTCCTCTTCAAGACAAAGGGAATAGTACTCATAGTAGAAAT
AACAGCTATGCAGTGATTATCACCAGCACCAGTTCGTATTATGTGTTTTACATTTACGTG
GGAGTAGCCGACACTTTGCTTGCTATGGGATTCTTCAGAGGTCTACCACTGGTGCATACT
CTAATCACAGTGTCGAAAATTTTACACCACAAAATGTTACATTCTGTTCTTCAAGCACCT
ATGTCAACCCTCAACACGTTGAAAGCAGGTGGGATTCTTAATAGATTCTCCAAAGATATA
GCAATTTTGGATGACCTTCTGCCTCTTACCATATTTGACTTCATCCAGTTGTTATTAATT
GTGATTGGAGCTATAGCAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAACAGTG
CCAGTGATAGTGGCTTTTATTATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTC
AAACAACTGGAATCTGAAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAAAA
GGACTATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAA
GCTCTGAATTTACATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAA
ATGAGAATAGAAATGATTTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTA
ACAACAGGAGAAGGAGAAGGAAGAGTTGGTATTATCCTGACTTTAGCCATGAATATCATG
AGTACATTGCAGTGGGCTGTAAACTCCAGCATAGATGTGGATAGCTTGATGCGATCTGTG
AGCCGAGTCTTTAAGTTCATTGACATGCCAACAGAAGGTAAACCTACCAAGTCAACCAAA
CCATACAAGAATGGCCAACTCTCGAAAGTTATGATTATTGAGAATTCACACGTGAAGAAA
GATGACATCTGGCCCTCAGGGGGCCAAATGACTGTCAAAGATCTCACAGCAAAATACACA
GAAGGTGGAAATGCCATATTAGAGAACATTTCCTTCTCAATAAGTCCTGGCCAGAGGGTG
GGCCTCTTGGGAAGAACTGGATCAGGGAAGAGTACTTTGTTATCAGCTTTTTTGAGACTA
CTGAACACTGAAGGAGAAATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAA
CAGTGGAGGAAAGCCTTTGGAGTGATACCACAGAAAGTATTTATTTTTTCTGGAACATTT
AGAAAAAACTTGGATCCCTATGAACAGTGGAGTGATCAAGAAATATGGAAAGTTGCAGAT
GAGGTTGGGCTCAGATCTGTGATAGAACAGTTTCCTGGGAAGCTTGACTTTGTCCTTGTG
GATGGGGGCTGTGTCCTAAGCCATGGCCACAAGCAGTTGATGTGCTTGGCTAGATCTGTT
CTCAGTAAGGCGAAGATCTTGCTGCTTGATGAACCCAGTGCTCATTTGGATCCAGTAACA
TACCAAATAATTAGAAGAACTCTAAAACAAGCATTTGCTGATTGCACAGTAATTCTCTGT
GAACACAGGATAGAAGCAATGCTGGAATGCCAACAATTTTTGGTCATAGAAGAGAACAAA
GTGCGGCAGTACGATTCCATCCAGAAACTGCTGAACGAGAGGAGCCTCTTCCGGCAAGCC
ATCAGCCCCTCCGACAGGGTGAAGCTCTTTCCCCACCGGAACTCAAGCAAGTGCAAGTCT
AAGCCCCAGATTGCTGCTCTGAAAGAGGAGACAGAAGAAGAGGTGCAAGATACAAGGCTT
TAG

# Drug_Target_15_General_Function:
Involved in chloride ion transport

# Drug_Target_15_General_References:
10094564	Picci L, Cameran M, Olante P, Zacchello F, Scarpa M: Identification of a D579G homozygote cystic fibrosis patient with pancreatic sufficiency and minor lung involvement. Mutations in brief no. 221. Online. Hum Mutat. 1999;13(2):173.
11304524	Karthikeyan S, Leung T, Ladias JA: Structural basis of the Na+/H+ exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator. J Biol Chem. 2001 Jun 8;276(23):19683-6. Epub 2001 Apr 13.
11707463	Cheng J, Moyer BD, Milewski M, Loffing J, Ikeda M, Mickle JE, Cutting GR, Li M, Stanton BA, Guggino WB: A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression. J Biol Chem. 2002 Feb 1;277(5):3520-9. Epub 2001 Nov 13.
12690205	Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katiraee L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, Pelicci PG, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Dohner H, Dohner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC: Human chromosome 7: DNA sequence and biology. Science. 2003 May 2;300(5620):767-72. Epub 2003 Apr 10.
1284466	Jones CT, McIntosh I, Keston M, Ferguson A, Brock DJ: Three novel mutations in the cystic fibrosis gene detected by chemical cleavage: analysis of variant splicing and a nonsense mutation. Hum Mol Genet. 1992 Apr;1(1):11-7.
1284468	Cheadle JP, Meredith AL, al-Jader LN: A new missense mutation (R1283M) in exon 20 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet. 1992 May;1(2):123-5.
1284529	Shackleton S, Beards F, Harris A: Detection of novel and rare mutations in exon 4 of the cystic fibrosis gene by SSCP. Hum Mol Genet. 1992 Sep;1(6):439-40.
1284530	Lissens W, Bonduelle M, Malfroot A, Dab I, Liebaers I: A serine to proline substitution (S1255P) in the second nucleotide binding fold of the cystic fibrosis gene. Hum Mol Genet. 1992 Sep;1(6):441-2.
1284534	Tsui LC: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat. 1992;1(3):197-203.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1377674	Picciotto MR, Cohn JA, Bertuzzi G, Greengard P, Nairn AC: Phosphorylation of the cystic fibrosis transmembrane conductance regulator. J Biol Chem. 1992 Jun 25;267(18):12742-52.
1378801	McIntosh I, Cutting GR: Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J. 1992 Jul;6(10):2775-82.
1695717	Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui LC, Antonarakis SE, Kazazian HH Jr: A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature. 1990 Jul 26;346(6282):366-9.
1710598	Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, Rommens J, Tsui LC: Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991 May;10(1):214-28.
1710600	White MB, Krueger LJ, Holsclaw DS Jr, Gerrard BC, Stewart C, Quittell L, Dolganov G, Baranov V, Ivaschenko T, Kapronov NI, et al.: Detection of three rare frameshift mutations in the cystic fibrosis gene in an African-American (CF444delA), an Italian (CF2522insC), and a Soviet (CF3821delT). Genomics. 1991 May;10(1):266-9.
2236053	Kerem BS, Zielenski J, Markiewicz D, Bozon D, Gazit E, Yahav J, Kennedy D, Riordan JR, Collins FS, Rommens JM, et al.: Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8447-51.
2475911	Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066-73.
7504969	Gasparini P, Marigo C, Bisceglia G, Nicolis E, Zelante L, Bombieri C, Borgo G, Pignatti PF, Cabrini G: Screening of 62 mutations in a cohort of cystic fibrosis patients from north eastern Italy: their incidence and clinical features of defined genotypes. Hum Mutat. 1993;2(5):389-94.
7505694	Chillon M, Casals T, Nunes V, Gimenez J, Perez Ruiz E, Estivill X: Identification of a new missense mutation (P205S) in the first transmembrane domain of the CFTR gene associated with a mild cystic fibrosis phenotype. Hum Mol Genet. 1993 Oct;2(10):1741-2.
7513296	Boteva K, Papageorgiou E, Georgiou C, Angastiniotis M, Middleton LT, Constantinou-Deltas CD: Novel cystic fibrosis mutation associated with mild disease in Cypriot patients. Hum Genet. 1994 May;93(5):529-32.
7517264	Chillon M, Casals T, Gimenez J, Nunes V, Estivill X: Analysis of the CFTR gene in the Spanish population: SSCP-screening for 60 known mutations and identification of four new mutations (Q30X, A120T, 1812-1 G-->A, and 3667del4). Hum Mutat. 1994;3(3):223-30.
7520022	Greil I, Wagner K, Rosenkranz W: A new missense mutation G1249E in exon 20 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Hum Hered. 1994 Jul-Aug;44(4):238-40.
7522211	Ghanem N, Costes B, Girodon E, Martin J, Fanen P, Goossens M: Identification of eight mutations and three sequence variations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1994 May 15;21(2):434-6.
7524909	Schaedel C, Kristoffersson AC, Kornfalt R, Holmberg L: A novel cystic fibrosis mutation, Y109C, in the first transmembrane domain of CFTR. Hum Mol Genet. 1994 Jun;3(6):1001-2.
7524913	Petreska L, Koceva S, Gordova-Muratovska A, Nestorov R, Efremov GD: Identification of two new mutations (711 +3A-->G and V1397E) in CF chromosomes of Albanian and Macedonian origin. Hum Mol Genet. 1994 Jun;3(6):999-1000.
7525450	Dork T, Mekus F, Schmidt K, Bosshammer J, Fislage R, Heuer T, Dziadek V, Neumann T, Kalin N, Wulbrand U, et al.: Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. Hum Genet. 1994 Nov;94(5):533-42.
7529962	Mercier B, Verlingue C, Lissens W, Silber SJ, Novelli G, Bonduelle M, Audrezet MP, Ferec C: Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients. Am J Hum Genet. 1995 Jan;56(1):272-7.
7537150	Zielenski J, Markiewicz D, Chen HS, Schappert K, Seller A, Durie P, Corey M, Tsui LC: Identification of six mutations (R31L, 441delA, 681delC, 1461ins4, W1089R, E1104X) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Hum Mutat. 1995;5(1):43-7.
7539342	Jezequel P, Dorval I, Fergelot P, Chauvel B, Le Treut A, Le Gall JY, Le Lannou D, Blayau M: Structural analysis of CFTR gene in congenital bilateral absence of vas deferens. Clin Chem. 1995 Jun;41(6 Pt 1):833-5.
7541273	Verlingue C, Kapranov NI, Mercier B, Ginter EK, Petrova NV, Audrezet MP, Ferec C: Complete screening of mutations in the coding sequence of the CFTR gene in a sample of CF patients from Russia: identification of three novel alleles. Hum Mutat. 1995;5(3):205-9.
7541510	Ferec C, Novelli G, Verlingue C, Quere I, Dallapiccola B, Audrezet MP, Mercier B: Identification of six novel CFTR mutations in a sample of Italian cystic fibrosis patients. Mol Cell Probes. 1995 Apr;9(2):135-7.
7543567	Leoni GB, Pitzalis S, Podda R, Zanda M, Silvetti M, Caocci L, Cao A, Rosatelli MC: A specific cystic fibrosis mutation (T3381) associated with the phenotype of isolated hypotonic dehydration. J Pediatr. 1995 Aug;127(2):281-3.
7544319	Brancolini V, Cremonesi L, Belloni E, Pappalardo E, Bordoni R, Seia M, Russo S, Padoan R, Giunta A, Ferrari M: Search for mutations in pancreatic sufficient cystic fibrosis Italian patients: detection of 90% of molecular defects and identification of three novel mutations. Hum Genet. 1995 Sep;96(3):312-8.
7581407	Romey MC, Desgeorges M, Ray P, Godard P, Demaille J, Claustres M: Novel missense mutation in the first transmembrane segment of the CFTR gene (Q98R) identified in a male adult. Hum Mutat. 1995;6(2):190-1.
7680525	Zielenski J, Fujiwara TM, Markiewicz D, Paradis AJ, Anacleto AI, Richards B, Schwartz RH, Klinger KW, Tsui LC, Morgan K: Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population. Am J Hum Genet. 1993 Mar;52(3):609-15.
7683628	Mercier B, Lissens W, Novelli G, Kalaydjieva L, De Arce M, Kapranov N, Klain NC, Lenoir G, Chauveau P, Lenaerts C, et al.: Identification of eight novel mutations in a collaborative analysis of a part of the second transmembrane domain of the CFTR gene. Genomics. 1993 Apr;16(1):296-7.
7683954	Nunes V, Chillon M, Dork T, Tummler B, Casals T, Estivill X: A new missense mutation (E92K) in the first transmembrane domain of the CFTR gene causes a benign cystic fibrosis phenotype. Hum Mol Genet. 1993 Jan;2(1):79-80.
8081395	Bienvenu T, Petitpretz P, Beldjord C, Kaplan JC: A missense mutation (F87L) in exon 3 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mutat. 1994;3(4):395-6.
8522333	Desgeorges M, Rodier M, Piot M, Demaille J, Claustres M: Four adult patients with the missense mutation L206W and a mild cystic fibrosis phenotype. Hum Genet. 1995 Dec;96(6):717-20.
8723693	Petreska L, Plaseska D, Koceva S, Stavljenic-Rukavina A, Efremov GD: A novel mutation in exon 12 (Y569C) of the CFTR gene identified in a patient of Croatian origin. Hum Mutat. 1996;7(4):374-5.
8723695	Bienvenu T, Chertkoff L, Beldjord C, Segal E, Carniglia L, Barreiro C, Kaplan JC: Identification of three novel mutations in the cystic fibrosis transmembrane conductance regulator gene in Argentinian CF patients. Hum Mutat. 1996;7(4):376-7.
8800923	Messaoud T, Verlingue C, Denamur E, Pascaud O, Quere I, Fattoum S, Elion J, Ferec C: Distribution of CFTR mutations in cystic fibrosis patients of Tunisian origin: identification of two novel mutations. Eur J Hum Genet. 1996;4(1):20-4.
8829633	Nasr SZ, Strong TV, Mansoura MK, Dawson DC, Collins FS: Novel missense mutation (G314R) in a cystic fibrosis patient with hepatic failure. Hum Mutat. 1996;7(2):151-4.
8956039	Hughes DJ, Hill AJ, Macek M Jr, Redmond AO, Nevin NC, Graham CA: Mutation characterization of CFTR gene in 206 Northern Irish CF families: thirty mutations, including two novel, account for approximately 94% of CF chromosomes. Hum Mutat. 1996;8(4):340-7.
9067761	Zielenski J, Patrizio P, Markiewicz D, Asch RH, Tsui LC: Identification of two mutations (S50Y and 4173delC) in the CFTR gene from patients with congenital bilateral absence of vas deferens (CBAVD). Hum Mutat. 1997;9(2):183-4.
9101301	Clavel C, Pennaforte F, Pigeon F, Verlingue C, Birembaut P, Ferec C: Identification of four novel mutations in the cystic fibrosis transmembrane conductance regulator gene: E664X, 2113delA, 306delTAGA, and delta M1140. Hum Mutat. 1997;9(4):368-9.
9222768	Gouya L, Pascaud O, Munck A, Elion J, Denamur E: Novel mutation (A141D) in exon 4 of the CFTR gene identified in an Algerian patient. Hum Mutat. 1997;10(1):86-7.
9375855	Casals T, Pacheco P, Barreto C, Gimenez J, Ramos MD, Pereira S, Pinheiro JA, Cobos N, Curvelo A, Vazquez C, Rocha H, Seculi JL, Perez E, Dapena J, Carrilho E, Duarte A, Palacio AM, Nunes V, Lavinha J, Estivill X: Missense mutation R1066C in the second transmembrane domain of CFTR causes a severe cystic fibrosis phenotype: study of 19 heterozygous and 2 homozygous patients. Hum Mutat. 1997;10(5):387-92.
9385646	Neville DC, Rozanas CR, Price EM, Gruis DB, Verkman AS, Townsend RR: Evidence for phosphorylation of serine 753 in CFTR using a novel metal-ion affinity resin and matrix-assisted laser desorption mass spectrometry. Protein Sci. 1997 Nov;6(11):2436-45.
9401006	Shrimpton AE, Borowitz D, Swender P: Cystic fibrosis mutation frequencies in upstate New York. Hum Mutat. 1997;10(6):436-42.
9443874	Friedman KJ, Leigh MW, Czarnecki P, Feldman GL: Cystic fibrosis transmembrane-conductance regulator mutations among African Americans. Am J Hum Genet. 1998 Jan;62(1):195-6.
9452048	Feldmann D, Sardet A, Cougoureux E, Plouvier E, Fontaine JL, Tournier G, Aymard P: Identification of three novel mutations in the CFTR gene, R117P, deltaD192, and 3121-1G-->A in four French patients. Hum Mutat. 1998;Suppl 1:S78-80.
9452054	Casals T, Ramos MD, Gimenez J, Nadal M, Nunes V, Estivill X: Paternal origin of a de novo novel CFTR mutation (L1065R) causing cystic fibrosis. Hum Mutat. 1998;Suppl 1:S99-102.
9452073	Shackleton S, Harris A: A 2-amino acid insertion mutation (1243insACAAAA) in exon 7 of the CFTR gene. Hum Mutat. 1998;Suppl 1:S156-7.
9482579	Malone G, Haworth A, Schwarz MJ, Cuppens H, Super M: Detection of five novel mutations of the cystic fibrosis transmembrane regulator (CFTR) gene in Pakistani patients with cystic fibrosis: Y569D, Q98X, 296+12(T>C), 1161delC and 621+2(T>C). Hum Mutat. 1998;11(2):152-7.
9517543	Hoedemaeker FJ, Davidson AR, Rose DR: A model for the nucleotide-binding domains of ABC transporters based on the large domain of aspartate aminotransferase. Proteins. 1998 Feb 15;30(3):275-86.
9521595	Onay T, Topaloglu O, Zielenski J, Gokgoz N, Kayserili H, Camcioglu Y, Cokugras H, Akcakaya N, Apak M, Tsui LC, Kirdar B: Analysis of the CFTR gene in Turkish cystic fibrosis patients: identification of three novel mutations (3172delAC, P1013L and M1028I). Hum Genet. 1998 Feb;102(2):224-30.
9554753	Leoni GB, Pitzalis S, Tonelli R, Cao A: Identification of a novel mutation (S13F) in the CFTR gene in a CF patient of Sardinian origin. Hum Mutat. 1998;11(4):337.
9736778	Vankeerberghen A, Wei L, Jaspers M, Cassiman JJ, Nilius B, Cuppens H: Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator. Hum Mol Genet. 1998 Oct;7(11):1761-9.
9921909	Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gile LS, Luisetti M, Pignatti PF: Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet. 1998 Dec;103(6):718-22.

# Drug_Target_15_HGNC_ID:
HGNC:1884

# Drug_Target_15_HPRD_ID:
03883

# Drug_Target_15_ID:
2184

# Drug_Target_15_Locus:
7q31.2

# Drug_Target_15_Molecular_Weight:
168144

# Drug_Target_15_Name:
Cystic fibrosis transmembrane conductance regulator

# Drug_Target_15_Number_of_Residues:
1480

# Drug_Target_15_PDB_ID:
1XMI

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00005	ABC_tran
PF00664	ABC_membrane

# Drug_Target_15_Protein_Sequence:
>Cystic fibrosis transmembrane conductance regulator
MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRE
LASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNS
ILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQ
MNGIEEDSDEPLERRLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESI
PAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAP
MSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATV
PVIVAFIMLRAYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQIIRRTLKQAFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQA
ISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter

# Drug_Target_15_SwissProt_ID:
P13569

# Drug_Target_15_SwissProt_Name:
CFTR_HUMAN

# Drug_Target_15_Synonyms:
ATP-binding cassette transporter sub- family C member 7
CFTR
cAMP- dependent chloride channel

# Drug_Target_15_Theoretical_pI:
9.02

# Drug_Target_15_Transmembrane_Regions:
81-103
118-138
195-215
221-241
308-328
331-350
860-880
912-932
991-1011
1014-1034
1103-1123
1129-1149

# Drug_Target_16_Cellular_Location:
Cytoplasm. Membrane
peripheral membrane protein. Note=Membrane-associated after cell stimulation le

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
PDPK1

# Drug_Target_16_GenBank_ID_Gene:
AF017995

# Drug_Target_16_GenBank_ID_Protein:
2407613

# Drug_Target_16_GeneCard_ID:
PDPK1

# Drug_Target_16_Gene_Name:
PDPK1

# Drug_Target_16_Gene_Sequence:
>1671 bp
ATGGCCAGGACCACCAGCCAGCTGTATGACGCCGTGCCCATCCAGTCCAGCGTGGTGTTA
TGTTCCTGCCCATCCCCATCAATGGTGAGGACCCAGACTGAGTCCAGCACGCCCCCTGGC
ATTCCTGGTGGCAGCAGGCAGGGCCCCGCCATGGACGGCACTGCAGCCGAGCCTCGGCCC
GGCGCCGGCTCCCTGCAGCATGCCCAGCCTCCGCCGCAGCCTCGGAAGAAGCGGCCTGAG
GACTTCAAGTTTGGGAAAATCCTTGGGGAAGGCTCTTTTTCCACGGTTGTCCTGGCTCGA
GAACTGGCAACCTCCAGAGAATATGCGATTAAAATTCTGGAGAAGCGACATATCATAAAA
GAGAACAAGGTCCCCTATGTAACCAGAGAGCGGGATGTCATGTCGCGCCTGGATCACCCC
TTCTTTGTTAAGCTTTACTTCACATTTCAGGACGACGAGAAGCTGTATTTCGGCCTTAGT
TATGCCAAAAATGGAGAACTACTTAAATATATTCGCAAAATCGGTTCATTCGATGAGACC
TGTACCCGATTTTACACGGCTGAGATCGTGTCTGCTTTAGAGTACTTGCACGGCAAGGGC
ATCATTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGAAGATATGCACATCCAG
ATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAAC
TCATTCGTGGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGT
AAGAGTTCAGACCTTTGGGCTCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCA
CCATTCCGAGCTGGAAACGAGTATCTTATATTTCAGAAGATCATTAAGTTGGAATATGAC
TTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTGGAGAAACTTTTGGTTTTAGAT
GCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAAGCACACCCG
TTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCT
TACCTGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTG
AGCCAGTTTGGCTGCATGCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCC
GACACGGGCCTGCCCCAGAGGTCAGGCAGCAACATAGAGCAGTACATTCACGATCTGGAC
TCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGAAGAGGTTGTTGTTGGAG
AAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAATACTAAAGATG
GGCCCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAA
GGACCACATTTATATTATGTGGATCCTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGG
TCACAAGAACTTCGACCAGAGGCCAAGAATTTTAAAACTTTCTTTGTCCACACGCCTAAC
AGGACGTATTATCTGATGGACCCCAGCGGGAACGCACACAAGTGGTGCAGGAAGATCCAG
GAGGTTTGGAGGCAGCGATACCAGAGCCACCCGGACGCCGCTGTGCAGTGA

# Drug_Target_16_General_Function:
Involved in protein kinase activity

# Drug_Target_16_General_References:
10364160	Paradis S, Ailion M, Toker A, Thomas JH, Ruvkun G: A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 1999 Jun 1;13(11):1438-52.
10455013	Casamayor A, Morrice NA, Alessi DR: Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J. 1999 Sep 1;342 ( Pt 2):287-92.
11481331	Park J, Hill MM, Hess D, Brazil DP, Hofsteenge J, Hemmings BA: Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity. J Biol Chem. 2001 Oct 5;276(40):37459-71. Epub 2001 Jul 31.
9094314	Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997 Apr 1;7(4):261-9.
9368760	Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes M: 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol. 1997 Oct 1;7(10):776-89.
9445477	Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT: Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 1998 Jan 30;279(5351):710-4.
9637919	Anderson KE, Coadwell J, Stephens LR, Hawkins PT: Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr Biol. 1998 Jun 4;8(12):684-91.

# Drug_Target_16_HGNC_ID:
HGNC:8816

# Drug_Target_16_HPRD_ID:
05556

# Drug_Target_16_ID:
2180

# Drug_Target_16_Locus:
16p13.3

# Drug_Target_16_Molecular_Weight:
63152

# Drug_Target_16_Name:
3-phosphoinositide-dependent protein kinase 1

# Drug_Target_16_Number_of_Residues:
556

# Drug_Target_16_PDB_ID:
2BIY

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_16_Protein_Sequence:
>3-phosphoinositide-dependent protein kinase 1
MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRP
GAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIK
ENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDET
CTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARAN
SFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYD
FPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTA
YLPAMSEDDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLD
SNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTE
GPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQ
EVWRQRYQSHPDAAVQ

# Drug_Target_16_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Phosphorylates and activates not only PKB/AKT, but also PKA, PKC-zeta, RPS6KA1 and RPS6KB1. May play a general role in signaling processes and in development. Isoform 3 is catalytically inactive

# Drug_Target_16_SwissProt_ID:
O15530

# Drug_Target_16_SwissProt_Name:
PDPK1_HUMAN

# Drug_Target_16_Synonyms:
EC 2.7.11.1
hPDK1

# Drug_Target_16_Theoretical_pI:
7.38

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Isoform 2:Cytoplasm. Nucleus. Isoform 1:Cell membrane

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
PIM1

# Drug_Target_17_GenBank_ID_Gene:
M27903

# Drug_Target_17_GenBank_ID_Protein:
387022

# Drug_Target_17_GeneCard_ID:
PIM1

# Drug_Target_17_Gene_Name:
PIM1

# Drug_Target_17_Gene_Sequence:
>1215 bp
CTGCCGCACGAGCCCCACGAGCCGCTCACCCCGCCGTTCTCAGCGCTGCCCGACCCCGCT
GGCGCGCCCTCCCGCCGCCAGTCCCGGCAGCGCCCTCAGTTGTCCTCCGACTCGCCCTCG
GCCTTCCGCGCCAGCCGCAGCCACAGCCGCAACGCCACCCGCAGCCACAGCCACAGCCAC
AGCCCCAGGCATAGCCTTCGGCACAGCCCCGGCTCCGGCTCCTGCGGCAGCTCCTCTGGG
CACCGTCCCTGCGCCGACATCCTGGAGGTTGGGATGCTCTTGTCCAAAATCAACTCGCTT
GCCCACCTGCGCGCCGCGCCCTGCAACGACCTGCACGCCACCAAGCTGGCGCCCGGCAAG
GAGAAGGAGCCCCTGGAGTCGCAGTACCAGGTGGGCCCGCTACTGGGCAGCGGCGGCTTC
GGCTCGGTCTACTCAGGCATCCGCGTCTCCGACAACTTGCCGGTGGCCATCAAACACGTG
GAGAAGGACCGGATTTCCGACTGGGGAGAGCTGCCTAATGGCACTCGAGTGCCCATGGAA
GTGGTCCTGCTGAAGAAGGTGAGCTCGGGTTTCTCCGGCGTCATTAGGCTCCTGGACTGG
TTCGAGAGGCCCGACAGTTTCGTCCTGATCCTGGAGAGGNCCGAGCCGGTGCAAGATCTC
TTCGACTTCATCACGGAAAGGGGAGCCCTGCAAGAGGAGCTGGCCCGCAGCTTCTTCTGG
CAGGTGCTGGAGGCCGTGCGGCACTGCCACAACTGCGGGGTGCTCCACCGCGACATCAAG
GACGAAAACATCCTTATCGACCTCAATCGCGGCGAGCTCAAGCTCATCGACTTCGGGTCG
GGGGCGCTGCTCAAGGACACCGTCTACACGGACTTCGATGGGACCCGAGTGTATAGCCCT
CCAGAGTGGATCCGCTACCATCGCTACCATGGCAGGTCGGCGGCAGTCTGGTCCCTGGGG
ATCCTGCTGTATGATATGGTGTGTGGAGATATTCCTTTCGAGCATGACGAAGAGATCATC
AGGGGCCAGGTTTTCTTCAGGCAGAGGGTCTCTTCAGAATGTCAGCATCTCATTAGATGG
TGCTTGGCCCTGAGACCATCAGATAGGCCAACCTTCGAAGAAATCCAGAACCATCCATGG
ATGCAAGATGTTCTCCTGCCCCAGGAAACTGCTGAGATCCACCTCCACAGCCTGTCGCCG
GGGCCCAGCAAATAG

# Drug_Target_17_General_Function:
Involved in protein kinase activity

# Drug_Target_17_General_References:
10664448	Koike N, Maita H, Taira T, Ariga H, Iguchi-Ariga SM: Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett. 2000 Feb 4;467(1):17-21.
11460166	Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, Dalla-Favera R: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001 Jul 19;412(6844):341-6.
12680209	Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS: Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb;23(1A):167-78.
2205533	Reeves R, Spies GA, Kiefer M, Barr PJ, Power M: Primary structure of the putative human oncogene, pim-1. Gene. 1990 Jun 15;90(2):303-7.
2837645	Telerman A, Amson R, Zakut-Houri R, Givol D: Identification of the human pim-1 gene product as a 33-kilodalton cytoplasmic protein with tyrosine kinase activity. Mol Cell Biol. 1988 Apr;8(4):1498-503.
3329709	Domen J, Von Lindern M, Hermans A, Breuer M, Grosveld G, Berns A: Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence and immunological identification of the in vitro synthesized PIM-1 protein. Oncogene Res. 1987 Jun;1(1):103-12.
3429489	Meeker TC, Nagarajan L, ar-Rushdi A, Croce CM: Cloning and characterization of the human PIM-1 gene: a putative oncogene related to the protein kinases. J Cell Biochem. 1987 Oct;35(2):105-12.
3475233	Zakut-Houri R, Hazum S, Givol D, Telerman A: The cDNA sequence and gene analysis of the human pim oncogene. Gene. 1987;54(1):105-11.

# Drug_Target_17_HGNC_ID:
HGNC:8986

# Drug_Target_17_HPRD_ID:
01292

# Drug_Target_17_ID:
2347

# Drug_Target_17_Locus:
6p21.2

# Drug_Target_17_Molecular_Weight:
45413

# Drug_Target_17_Name:
Proto-oncogene serine/threonine-protein kinase Pim-1

# Drug_Target_17_Number_of_Residues:
404

# Drug_Target_17_PDB_ID:
1XWS

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_17_Protein_Sequence:
>Proto-oncogene serine/threonine-protein kinase Pim-1
MPHEPHEPLTPPFSALPDPAGAPSRRQSRQRPQLSSDSPSAFRASRSHSRNATRSHSHSH
SPRHSLRHSPGSGSCGSSSGHRPCADILEVGMLLSKINSLAHLRAAPCNDLHATKLAPGK
EKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPME
VVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFW
QVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSP
PEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRW
CLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK

# Drug_Target_17_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Plays a role in signal transduction in blood cells. Contributes to both cell proliferation and survival and thus provide a selective advantage in tumorigenesis. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3

# Drug_Target_17_SwissProt_ID:
P11309

# Drug_Target_17_SwissProt_Name:
PIM1_HUMAN

# Drug_Target_17_Synonyms:
EC 2.7.11.1

# Drug_Target_17_Theoretical_pI:
7.01

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
PRKCQ

# Drug_Target_18_GenBank_ID_Gene:
L01087

# Drug_Target_18_GenBank_ID_Protein:
558099

# Drug_Target_18_GeneCard_ID:
PRKCQ

# Drug_Target_18_Gene_Name:
PRKCQ

# Drug_Target_18_Gene_Sequence:
>2121 bp
ATGTCGCCATTTCTTCGGATTGGCTTGTCCAACTTTGACTGCGGGTCCTGCCAGTCTTGT
CAGGGCGAGGCTGTTAACCCTTACTGTGCTGTGCTCGTCAAAGAGTATGTCGAATCAGAG
AACGGGCAGATGTATATCCAGAAAAAGCCTACCATGTACCCACCCTGGGACAGCACTTTT
GATGCCCATATCAACAAGGGAAGAGTCATGCAGATCATTGTGAAAGGCAAAAACGTGGAC
CTCATCTCTGAAACCACCGTGGAGCTCTACTCGCTGGCTGAGAGGTGCAGGAAGAACAAC
GGGAAGACAGAAATATGGTTAGAGCTGAAACCTCAAGGCCGAATGCTAATGAATGCAAGA
TACTTTCTGGAAATGAGTGACACAAAGGACATGAATGAATTTGAGACGGAAGGCTTCTTT
GCTTTGCATCAGCGCCGGGGTGCCATCAAGCAGGCAAAGGTCCACCACGTCAAGTGCCAC
GAGTTCACTGCCACCTTCTTCCCACAGCCCACATTTTGCTCTGTCTGCCACGAGTTTGTC
TGGGGCCTGAACAAACAGGGCTACCAGTGCCGACAATGCAATGCAGCAATTCACAAGAAG
TGTATTGATAAAGTTATAGCAAAGTGCACAGGATCAGCTATCAATAGCCGAGAAACCATG
TTCCACAAGGAGAGATTCAAAATTGACATGCCACACAGATTTAAAGTCTACAATTACAAG
AGCCCGACCTTCTGTGAACACTGTGGGACCCTGCTGTGGGGACTGGCACGGCAAGGACTC
AAGTGTGATGCATGTGGCATGAATGTGCATCATAGATGCCAGACAAAGGTGGCCAACCTT
TGTGGCATAAACCAGAAGCTAATGGCTGAAGCGCTGGCCATGATTGAGAGCACTCAACAG
GCTCGCTGCTTAAGAGATACTGAACAGATCTTCAGAGAAGGTCCGGTTGAAATTGGTCTC
CCATGCTCCATCAAAAATGAAGCAAGGCTGCCATGTTTACCGACACCGGGAAAAAGAGAG
CCTCAGGGCATTTCCTGGGAGTCTCCGTTGGATGAGGTGGATAAAATGTGCCATCTTCCA
GAACCTGAACTGAACAAAGAAAGACCATCTCTGCAGATTAAACTAAAAATTGAGGATTTT
ATCTTGCACAAAATGTTGGGGAAAGGAAGTTTTGGCAAGGTCTTCCTGGCAGAATTCAAG
AAAACCAATCAATTTTTCGCAATAAAGGCCTTAAAGAAAGATGTGGTCTTGATGGACGAT
GATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTGGCCTGGGAGCATCCGTTT
CTGACGCACATGTTTTGTACATTTCAGACCAAGGAAAACCTCTTTTTTGTGATGGAGTAC
CTCAACGGAGGGGACTTAATGTACCACATCCAAAGCTGCCACAAGTTCGACCTTTCCAGA
GCGACGTTTTATGCTGCTGAAATCATTCTTGGTCTGCAGTTCCTTCATTCCAAAGGAATA
GTCTACAGGGACCTGAAGCTAGATAACATCCTGTTAGACAAAGATGGACATATCAAGATC
GCGGATTTTGGAATGTGCAAGGAGAACATGTTAGGAGATGCCAAGACGAATACCTTCTGT
GGGACACCTGACTACATCGCCCCAGAGATCTTGCTGGGTCAGAAATACAACCACTCTGTG
GACTGGTGGTCCTTCGGGGTTCTCCTTTATGAAATGCTGATTGGTCAGTCGCCTTTCCAC
GGGCAGGATGAGGAGGAGCTCTTCCACTCCATCCGCATGGACAATCCCTTTTACCCACGG
TGGCTGGAGAAGGAAGCAAAGGACCTTCTGGTGAAGCTCTTCGTGCGAGAACCTGAGAAG
AGGCTGGGCGTGAGGGGAGACATCCGCCAGCACCCTTTGTTTCGGGAGATCAACTGGGAG
GAACTTGAACGGAAGGAGATTGACCCACCGTTCCGGCCGAAAGTGAAATCACCATTTGAC
TGCAGCAATTTCGACAAAGAATTCTTAAACGAGAAGCCCCGGCTGTCATTTGCCGACAGA
GCACTGATCAACAGCATGGACCAGAATATGTTCAGGAACTTTTCCTTCATGAACCCCCGG
ATGGAGCGGCTGATATCCTGA

# Drug_Target_18_General_Function:
Involved in protein serine/threonine kinase activity

# Drug_Target_18_General_References:
10636891	Witte S, Villalba M, Bi K, Liu Y, Isakov N, Altman A: Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem. 2000 Jan 21;275(3):1902-9.
7686153	Chang JD, Xu Y, Raychowdhury MK, Ware JA: Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets. J Biol Chem. 1993 Jul 5;268(19):14208-14.
8444877	Baier G, Telford D, Giampa L, Coggeshall KM, Baier-Bitterlich G, Isakov N, Altman A: Molecular cloning and characterization of PKC theta, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells. J Biol Chem. 1993 Mar 5;268(7):4997-5004.

# Drug_Target_18_HGNC_ID:
HGNC:9410

# Drug_Target_18_HPRD_ID:
02710

# Drug_Target_18_ID:
2530

# Drug_Target_18_Locus:
10p15

# Drug_Target_18_Molecular_Weight:
81866

# Drug_Target_18_Name:
Protein kinase C theta type

# Drug_Target_18_Number_of_Residues:
706

# Drug_Target_18_PDB_ID:
1XJD

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00069	Pkinase
PF00130	C1_1
PF00433	Pkinase_C

# Drug_Target_18_Protein_Sequence:
>Protein kinase C theta type
MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTF
DAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCRKNNGKTEIWLELKPQGRMLMNAR
YFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCHEFTATFFPQPTFCSVCHEFV
WGLNKQGYQCRQCNAAIHKKCIDKVIAKCTGSAINSRETMFHKERFKIDMPHRFKVYNYK
SPTFCEHCGTLLWGLARQGLKCDACGMNVHHRCQTKVANLCGINQKLMAEALAMIESTQQ
ARCLRDTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDKMCHLP
EPELNKERPSLQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDD
DVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSR
ATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNTFC
GTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPR
WLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFD
CSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS

# Drug_Target_18_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
PKC is activated by diacylglycerol which in turn phosphorylates a range of cellular proteins. PKC also serves as the receptor for phorbol esters, a class of tumor promoters

# Drug_Target_18_SwissProt_ID:
Q04759

# Drug_Target_18_SwissProt_Name:
KPCT_HUMAN

# Drug_Target_18_Synonyms:
EC 2.7.11.13
nPKC-theta

# Drug_Target_18_Theoretical_pI:
7.64

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
PYGL

# Drug_Target_19_GenBank_ID_Gene:
M14636

# Drug_Target_19_GenBank_ID_Protein:
183353

# Drug_Target_19_GeneCard_ID:
PYGL

# Drug_Target_19_Gene_Name:
PYGL

# Drug_Target_19_Gene_Sequence:
>2544 bp
ATGGGCGAACCGCTGACAGACCAGGAGAAGCGGCGGCAGATCAGCATCCGCGGCATCGTG
GGCGTGGAGAACGTGGCAGAGCTGAAGAAGAGTTTCAACCGGCACCTGCACTTCACGCTG
GTCAAGGACCGCAACGTGGCCACCACCCGCGACTACTACTTCGCGCTGGCGCACACGGTG
CGGGACCACCTGGTGGGGCGCTGGATCCGCACGCAGCAGCACTACTACGACAAGTGCCCC
AAGAGGGAATATTACCTCTCTCTGGAATTTTACATGGGCCGAACATTACAGAACACCATG
ATCAACCTCGGTCTGCAAAATGCCTGTGATGAGGCCATTTACCAGCTTGGATTGGATATA
GAAGAGTTAGAAGAAATTGAAGAAGATGCTGGACTTGGCAATGGTGGTCTTGGGAGACTT
GCTGCCTGCTTCTTGGATTCCATGGCAACCCTGGGACTTGCAGCCTATGGATACGGCATT
CGGTATGAATATGGGATTTTCAATCAGAAGATCCGAGATGGATGGCAGGTAGAAGAAGCA
GATGATTGGCTCAGATATGGAAACCCTTGGGAGAAGTCCCGCCCAGAATTCATGCTGCCT
GTGCACTTCTATGGAAAAGTAGAACACACCAACACCGGGACCAAGTGGATTGACACTCAA
GTGGTCCTGGCTCTGCCATATGACACCCCCGAGCCCGGCTACATGAATAACACTGTCAAC
ACCATGCGCCTCTGGTCTGCTCGGGCACCAAATGACTTTAACCTCAGAGACTTTAATGTT
GGAGACTACATTCAGGCTGTGCTGGACCGAAACCTGGCCGAGAACATCTCCCGGGTCCTC
TATCCCAATGACAATTTTTTTGAAGGGAAGGAGCTAAGATTGAAGCAGGAATACTTTGTG
GTGGCTGCAACCTTGCAAGATATCATCCGCCGTTTCAAAGCCTCCAAGTTTGGCTCCACC
CGTGGTCAAGGAACTGTGTTTGATGCCTTCCCGGATCAGGTGGCCATCCAGCTGAATGAT
ACTCACCCTCGCATCGCGATCCCTGAGCTGATGAGGATTTTTGTGGATATTGAAAAACTG
CCCTGGTCCAAGGCATGGGAGCTCAACCAGAAGACCTTCGCCTACACCAACCACACAGTG
CTCCCGGAAGCCCTGGAGCGCTGGCCCGTGGACCTGGTGGAGAAGCTGCTCCCTCGACAT
TTGGAAATCATTTATGAGATAAATCAGAAGCATTTAGATAGAATTGTGGCCTTGTTTCCT
AAAGATGTGGACCCTCTGAGAAGGATGTCTCTGATAGAAGAGGAAGGAAGCAAAAGGATC
AACATGGCCCATCTCTGCATTGTCGGTTCCCATGCTGTGAATGGCGTGGCTAAAATCCAC
TCAGACATCGTGAAGACTAAAGTATTCAAGGACTTCAGTGAGCTAGAACCTGACAAGTTT
CAGAATAAAACCAATGGGATCACTCCAAGGCGCTGGCTCCTACTCTGCAACCCAGGACTT
GCAGAGCTCATAGCAGAGAAAATTGGAGAAGACTATGTGAAAGACCTGAGCCAGCTGACG
AAGCTCCACAGCTTCCTGGGTGATGATGTCTTCCTCCGGGAACTCGCCAAGGTGAAGCAG
GAGAATAAGCTGAAGTTTTCTCAGTTCCTGGAGACGGAGTACAAAGTGAAGATCAACCCA
TCCTCCATGTTTGATGTCCAGGTGAAGAGGATACATGAGTACAAGCGACAGCTCTTGAAC
TGTCTGCATGTGATCACGATGTACAACCGCATTAAGAAAGACCCTAAGAAGTTATTCGTG
CCAAGGACAGTTATCATTGGTGGTAAAGCTGCCCCAGGATATCACATGGCCAAAATGATC
ATAAAGCTGATCACTTCAGTGGCAGATGTGGTGAACAATGACCCTATGGTTGGAAGCAAG
TTGAAAGTCATCTTCTTGGAGAACTACAGAGTATCTCTTGCTGAAAAAGTCATTCCAGCC
ACAGATCTGTCAGAGCAGATTTCCACTGCAGGCACCGAAGCCTCGGGGACAGGCAATATG
AAGTTCATGCTAAATGGGGCCCTAACTATCGGGACCATGGATGGGGCCAATGTGGAAATG
GCAGAAGAAGCTGGGGAAGAGAACCTGTTCATCTTTGGCATGAGCATAGATGATGTGGCT
GCTTTGGACAAGAAAGGGTACGAGGCAAAAGAATACTATGAGGCACTTCCAGAGCTGAAG
CTGGTCATTGATCAAATTGACAATGGCTTTTTTTCTCCCAAGCAGCCTGACCTCTTCAAA
GATATCATCAACATGCTATTTTATCATGACAGGTTTAAAGTCTTTGCAGACTACGAAGCC
TATGTCAAGTGTCAAGATAAAGTGAGTCAGCTGTACATGAATCCAAAGGCCTGGAACACA
ATGGTACTCAAAAACATAGCTGCCTCGGGGAAATTCTCCAGTGACCGAACAATTAAAGAA
TATGCCCAAAACATCTGGAACGTGGAACCTTCAGATCTAAAGATTTCTCTATCCAATGAA
TCTAACAAAGTCAATGGAAATTGA

# Drug_Target_19_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_19_General_References:
10949035	Rath VL, Ammirati M, LeMotte PK, Fennell KF, Mansour MN, Danley DE, Hynes TR, Schulte GK, Wasilko DJ, Pandit J: Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol Cell. 2000 Jul;6(1):139-48.
10980448	Rath VL, Ammirati M, Danley DE, Ekstrom JL, Gibbs EM, Hynes TR, Mathiowetz AM, McPherson RK, Olson TV, Treadway JL, Hoover DJ: Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem Biol. 2000 Sep;7(9):677-82.
12204691	Ekstrom JL, Pauly TA, Carty MD, Soeller WC, Culp J, Danley DE, Hoover DJ, Treadway JL, Gibbs EM, Fletterick RJ, Day YS, Myszka DG, Rath VL: Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Chem Biol. 2002 Aug;9(8):915-24.
2877458	Newgard CB, Nakano K, Hwang PK, Fletterick RJ: Sequence analysis of the cDNA encoding human liver glycogen phosphorylase reveals tissue-specific codon usage. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8132-6.
3509980	Gorin FA, Mullinax RL, Ignacio PC, Neve RL, Kurnit DM: McArdle's & Hers' diseases: glycogen phosphorylase transcriptional expression in human tissues. J Neurogenet. 1987 Dec;4(6):293-308.
9529348	Burwinkel B, Bakker HD, Herschkovitz E, Moses SW, Shin YS, Kilimann MW: Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am J Hum Genet. 1998 Apr;62(4):785-91.
9536091	Chang S, Rosenberg MJ, Morton H, Francomano CA, Biesecker LG: Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI. Hum Mol Genet. 1998 May;7(5):865-70.

# Drug_Target_19_HGNC_ID:
HGNC:9725

# Drug_Target_19_HPRD_ID:
01987

# Drug_Target_19_ID:
10

# Drug_Target_19_Locus:
14q21-q22

# Drug_Target_19_Molecular_Weight:
97019

# Drug_Target_19_Name:
Glycogen phosphorylase, liver form

# Drug_Target_19_Number_of_Residues:
846

# Drug_Target_19_PDB_ID:
1L7X

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00343	Phosphorylase

# Drug_Target_19_Protein_Sequence:
>Glycogen phosphorylase, liver form
AKPLTDQEKRRQISIRGIVGVENVAELKKSFNRHLHFTLVKDRNVATTRDYYFALAHTVR
DHLVGRWIRTQQHYYDKCPKRVYYLSLEFYMGRTLQNTMINLGLQNACDEAIYQLGLDIE
ELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEYGIFNQKIRDGWQVEEAD
DWLRYGNPWEKSRPEFMLPVHFYGKVEHTNTGTKWIDTQVVLALPYDTPVPGYMNNTVNT
MRLWSARAPNDFNLRDFNVGDYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVV
AATLQDIIRRFKASKFGSTRGAGTVFDAFPDQVAIQLNDTHPALAIPELMRIFVDIEKLP
WSKAWELTQKTFAYTNHTVLPEALERWPVDLVEKLLPRHLEIIYEINQKHLDRIVALFPK
DVDRLRRMSLIEEEGSKRINMAHLCIVGSHAVNGVAKIHSDIVKTKVFKDFSELEPDKFQ
NKTNGITPRRWLLLCNPGLAELIAEKIGEDYVKDLSQLTKLHSFLGDDVFLRELAKVKQE
NKLKFSQFLETEYKVKINPSSMFDVQVKRIHEYKRQLLNCLHVITMYNRIKKDPKKLFVP
RTVIIGGKAAPGYHMAKMIIKLITSVADVVNNDPMVGSKLKVIFLENYRVSLAEKVIPAT
DLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENLFIFGMRIDDVAA
LDKKGYEAKEYYEALPELKLVIDQIDNGFFSPKQPDLFKDIINMLFYHDRFKVFADYEAY
VKCQDKVSQLYMNPKAWNTMVLKNIAASGKFSSDRTIKEYAQNIWNVEPSDLKISLSNES
NKVNGN

# Drug_Target_19_Reaction:
(1,4-alpha-D-glucosyl)n + phosphate = (1,4-alpha-D-glucosyl)n-1 + alpha-D-glucose 1-phosphate

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties

# Drug_Target_19_SwissProt_ID:
P06737

# Drug_Target_19_SwissProt_Name:
PYGL_HUMAN

# Drug_Target_19_Synonyms:
EC 2.4.1.1

# Drug_Target_19_Theoretical_pI:
7.17

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasm (By similarity). Nucleus (By similarity)

# Drug_Target_1_Chromosome_Location:
1

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X07767

# Drug_Target_1_GenBank_ID_Protein:
35479

# Drug_Target_1_GeneCard_ID:
PRKACA

# Drug_Target_1_Gene_Name:
PRKACA

# Drug_Target_1_Gene_Sequence:
>1056 bp
ATGGGCAACGCCGCCGCCGCCAAGAAGGGCAGCGAGCAGGAGAGCGTGAAAGAATTCTTA
GCCAAAGCCAAAGAAGATTTTCTTAAAAAATGGGAAAGTCCCGCTCAGAACACAGCCCAC
TTGGATCAGTTTGAACGAATCAAGACCCTCGGCACGGGCTCCTTCGGGCGGGTGATGCTG
GTGAAACACAAGGAGACCGGGAACCACTATGCCATGAAGATCCTCGACAAACAGAAGGTG
GTGAAACTGAAACAGATCGAACACACCCTGAATGAAAAGCGCATCCTGCAAGCTGTCAAC
TTTCCGTTCCTCGTCAAACTCGAGTTCTCCTTCAAGGACAACTCAAACTTATACATGGTC
ATGGAGTACGTGCCCGGCGGGGAGATGTTCTCACACCTACGGCGGATCGGAAGGTTCAGT
GAGCCCCATGCCCGTTTCTACGCGGCCCAGATCGTCCTGACCTTTGAGTATCTGCACTCG
CTGGATCTCATCTACAGGGACCTGAAGCCGGAGAATCTGCTCATTGACCAGCAGGGCTAC
ATTCAGGTGACAGACTTCGGTTTCGCCAAGCGCGTGAAGGGCCGCACTTGGACCTTGTGC
GGCACCCCTGAGTACCTGGCCCCTGAGATTATCCTGAGCAAAGGCTACAACAAGGCCGTG
GACTGGTGGGCCCTGGGGGTTCTTATCTATGAAATGGCCGCTGGCTACCCGCCCTTCTTC
GCAGACCAGCCCATCCAGATCTATGAGAAGATCGTCTCTGGGAAGGTGCGCTTCCCTTCC
CACTTCAGCTCTGACTTGAAGGACCTGCTGCGGAACCTCCTGCAGGTAGATCTCACCAAG
CGCTTTGGGAACCTCAAGAATGGGGTCAACGATATCAAGAACCACAAGTGGTTTGCCACA
ACTGACTGGATTGCCATCTACCAGAGGAAGGTGGAAGCTCCCTTCATACCAAAGTTTAAA
GGCCCTGGGGATACGAGTAACTTTGACGACTATGAGGAAGAAGAAATCCGGGTCTCCATC
AATGAGAAGTGTGGCAAGGAGTTTTCTGAGTTTTAG

# Drug_Target_1_General_Function:
Involved in ATP binding

# Drug_Target_1_General_References:
10841548	Desseyn JL, Burton KA, McKnight GS: Expression of a nonmyristylated variant of the catalytic subunit of protein kinase A during male germ-cell development. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6433-8.
10982398	Agustin JT, Wilkerson CG, Witman GB: The unique catalytic subunit of sperm cAMP-dependent protein kinase is the product of an alternative Calpha mRNA expressed specifically in spermatogenic cells. Mol Biol Cell. 2000 Sep;11(9):3031-44.
12509440	Ficarro S, Chertihin O, Westbrook VA, White F, Jayes F, Kalab P, Marto JA, Shabanowitz J, Herr JC, Hunt DF, Visconti PE: Phosphoproteome analysis of capacitated human sperm. Evidence of tyrosine phosphorylation of a kinase-anchoring protein 3 and valosin-containing protein/p97 during capacitation. J Biol Chem. 2003 Mar 28;278(13):11579-89. Epub 2002 Dec 30.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17081983	Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.
2843813	Maldonado F, Hanks SK: A cDNA clone encoding human cAMP-dependent protein kinase catalytic subunit C alpha. Nucleic Acids Res. 1988 Aug 25;16(16):8189-90.

# Drug_Target_1_HGNC_ID:
GNC:9380

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6263

# Drug_Target_1_Locus:
19p13.1

# Drug_Target_1_Molecular_Weight:
40589.4

# Drug_Target_1_Name:
cAMP-dependent protein kinase catalytic subunit alpha

# Drug_Target_1_Number_of_Residues:
351

# Drug_Target_1_PDB_ID:
1CTP

# Drug_Target_1_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Atenolol Pathway	SMP00298
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Carvedilol Pathway	SMP00367
Celecoxib Pathway	SMP00096
Citalopram Pathway	SMP00424
Desipramine Pathway	SMP00423
Escitalopram Pathway	SMP00425
Esmolol Pathway	SMP00301
Etodolac Pathway	SMP00084
Fluoxetine Pathway	SMP00426
Imipramine Pathway	SMP00422
Labetalol Pathway	SMP00368
Meloxicam Pathway	SMP00106
Metoprolol Pathway	SMP00302
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Pindolol Pathway	SMP00306
Propranolol Pathway	SMP00307
Rofecoxib Pathway	SMP00087
Valdecoxib Pathway	SMP00116

# Drug_Target_1_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_1_Protein_Sequence:
>cAMP-dependent protein kinase catalytic subunit alpha
MGNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVML
VKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMV
MEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQGY
IQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFF
ADQPIQIYEKIVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVNDIKNHKWFAT
TDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEFSEF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Phosphorylates a large number of substrates in the cytoplasm and the nucleus

# Drug_Target_1_SwissProt_ID:
P17612

# Drug_Target_1_SwissProt_Name:
KAPCA_HUMAN

# Drug_Target_1_Synonyms:
PKA C-alpha

# Drug_Target_1_Theoretical_pI:
9.22

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Not Available

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
M60873

# Drug_Target_20_GenBank_ID_Protein:
150994

# Drug_Target_20_GeneCard_ID:
Not Available

# Drug_Target_20_Gene_Name:
algC

# Drug_Target_20_Gene_Sequence:
>1392 bp
ATGAGCACTGTAAAAGCACCGACGCTGCCCGCCAGCATCTTCCGCGCCTACGACATCCGT
CGCGTGGTAGGCGATACCCTCACCGCCGAGACCGCCTACTGGATCGGTCGCGCCATCGGC
TCGGAAAGCCTCGCCCGCGGCGAACCGTGCGTCGCTGTCGGCCGCGATGGCCGCCTGTCC
GGTCCCGAGCTGGTCAAGCAGCTGATCCAGGGCCTGGTGGACTGCGGTTGCCAGGTCAGC
GACGTGGGCATGGTGCCTACCCCGGTGCTGTACTACGCGGCCAACGTGCTCGAGGGCAAG
TCCGGGGTGATGCTGACCGGCAGCCACAATCCGCCGGACTACAACGGCTTCAAGATCGTG
GTCGCCGGCGAGACCCTGGCCAACGAGCAGATCCAGGCCCTGCGCGAGCGCATCGAGAAA
AACGACCTGGCATCCGGCGTCGGCAGCGTAGAGCAGGTCGACATCCTGCCGCGCTACTTC
AAGCAGATCCGCGACGACATCGCCATGGCCAAGCCGATGAAGGTGGTGGTCGACTGCGGC
AACGGCGTGGCCGGGGTGATCGCCCCGCAGTTGATCGAGGCCCTGGGCTGCAGCGTGATC
CCGCTGTACTGCGAGGTCGACGGCAACTTCCCGAACCACCATCCGGACCCGGGCAAGCCG
GAGAACCTGAAGGACCTGATCGCCAAGGTCAAGGCCGAGAACGCCGACCTGGGCCTGGCC
TTCGACGGCGACGGCGATCGCGTCGGCGTGGTCACCAATACCGGTACCATCATCTATCCG
GACCGTCTGCTGATGCTGTTCGCCAAGGACGTGGTCTCGCGCAACCCGGGGGCCGACATC
ATCTTCGACGTCAAGTGCACCCGCCGTCTGATCGCCCTGATCAGCGGCTACGGCGGCCGT
CCGGTGATGTGGAAGACCGGCCACTCGCTGATCAAGAAGAAGATGAAGGAAACCGGCGCC
CTGCTGGCTGGCGAGATGAGCGGCCACGTGTTCTTCAAGGAGCGCTGGTTCGGCTTCGAC
GATGGCATCTACAGCGCCGCCCGCCTGCTGGAAATCCTCAGCCAGGATCAGCGTGACAGC
GAGCACGTGTTCTCGGCCTTCCCGAGCGACATTTCCACCCCGGAAATCAACATCACCGTC
ACCGAGGACAGCAAGTTCGCCATCATCGAGGCGCTGCAACGCGACGCCCAATGGGGCGAA
GGCAACATCACCACCCTCGACGGCGTGCGGGTCGACTACCCCAAAGGCTGGGGCCTGGTA
CGCGCCTCCAACACCACTCCCGTGCTGGTCCTGCGCTTCGAAGCGGACCCCGAGGAAGAG
CTGGAGCGCATCAAGACCGTCTTCCGTAACCAACTGAAGGCAGTGGATTCCTCGCTGCCC
GTGCCCTTCTGA

# Drug_Target_20_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_20_General_References:
10481091	Olvera C, Goldberg JB, Sanchez R, Soberon-Chavez G: The Pseudomonas aeruginosa algC gene product participates in rhamnolipid biosynthesis. FEMS Microbiol Lett. 1999 Oct 1;179(1):85-90.
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
11716469	Naught LE, Tipton PA: Kinetic mechanism and pH dependence of the kinetic parameters of Pseudomonas aeruginosa phosphomannomutase/phosphoglucomutase. Arch Biochem Biophys. 2001 Dec 1;396(1):111-8.
11839312	Regni C, Tipton PA, Beamer LJ: Crystal structure of PMM/PGM: an enzyme in the biosynthetic pathway of P. aeruginosa virulence factors. Structure. 2002 Feb;10(2):269-79.
1903398	Zielinski NA, Chakrabarty AM, Berry A: Characterization and regulation of the Pseudomonas aeruginosa algC gene encoding phosphomannomutase. J Biol Chem. 1991 May 25;266(15):9754-63.
7515870	Coyne MJ Jr, Russell KS, Coyle CL, Goldberg JB: The Pseudomonas aeruginosa algC gene encodes phosphoglucomutase, required for the synthesis of a complete lipopolysaccharide core. J Bacteriol. 1994 Jun;176(12):3500-7.
8050998	Ye RW, Zielinski NA, Chakrabarty AM: Purification and characterization of phosphomannomutase/phosphoglucomutase from Pseudomonas aeruginosa involved in biosynthesis of both alginate and lipopolysaccharide. J Bacteriol. 1994 Aug;176(16):4851-7.

# Drug_Target_20_HGNC_ID:
Not Available

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
2503

# Drug_Target_20_Locus:
Not Available

# Drug_Target_20_Molecular_Weight:
50296

# Drug_Target_20_Name:
Phosphomannomutase/phosphoglucomutase

# Drug_Target_20_Number_of_Residues:
463

# Drug_Target_20_PDB_ID:
1K2Y

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00408	PGM_PMM_IV
PF02878	PGM_PMM_I
PF02879	PGM_PMM_II
PF02880	PGM_PMM_III

# Drug_Target_20_Protein_Sequence:
>Phosphomannomutase/phosphoglucomutase
MSTAKAPTLPASIFRAYDIRGVVGDTLTAETAYWIGRAIGSESLARGEPCVAVGRDGRLS
GPELVKQLIQGLVDCGCQVSDVGMVPTPVLYYAANVLEGKSGVMLTGSHNPPDYNGFKIV
VAGETLANEQIQALRERIEKNDLASGVGSVEQVDILPRYFKQIRDDIAMAKPMKVVVDCG
NGVAGVIAPQLIEALGCSVIPLYCEVDGNFPNHHPDPGKPENLKDLIAKVKAENADLGLA
FDGDGDRVGVVTNTGTIIYPDRLLMLFAKDVVSRNPGADIIFDVKCTRRLIALISGYGGR
PVMWKTGHSLIKKKMKETGALLAGEMSGHVFFKERWFGFDDGIYSAARLLEILSQDQRDS
EHVFSAFPSDISTPEINITVTEDSKFAIIEALQRDAQWGEGNITTLDGVRVDYPKGWGLV
RASNTTPVLVLRFEADTEEELERIKTVFRNQLKAVDSSLPVPF

# Drug_Target_20_Reaction:
alpha-D-glucose 1-phosphate = D-glucose 6-phosphate

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
The phosphomannomutase activity produces a precursor for alginate polymerization. The alginate layer causes a mucoid phenotype and provides a protective barrier against host immune defenses and antibiotics. Also involved in core-LPS biosynthesis due to its phosphoglucomutase activity. Essential for rhamnolipid production, an exoproduct correlated with pathogenicity, and for biofilm production

# Drug_Target_20_SwissProt_ID:
P26276

# Drug_Target_20_SwissProt_Name:
ALGC_PSEAE

# Drug_Target_20_Synonyms:
EC 5.4.2.2
EC 5.4.2.8
PMM / PGM

# Drug_Target_20_Theoretical_pI:
4.95

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Not Available

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
PYGM

# Drug_Target_21_GenBank_ID_Gene:
M32598

# Drug_Target_21_GenBank_ID_Protein:
190784

# Drug_Target_21_GeneCard_ID:
PYGM

# Drug_Target_21_Gene_Name:
PYGM

# Drug_Target_21_Gene_Sequence:
>2529 bp
ATGTCCCGGCCCCTGTCAGACCAAGAGAAAAGAAAGCAAATCAGTGTGCGTGGCCTGGCC
GGCGTGGAGAACGTGACTGAGCTGAAAAAGAACTTCAACCGGCACCTGCATTTCACACTC
GTAAAGGACCGCAATGTGGCCACCCCACGAGACTACTACTTTGCTCTGGCCCATACCGTG
CGCGACCACCTCGTGGGGCGGTGGATCCGCACGCAGCAGCACTACTATGAGAAGGACCCC
AAGAGGATCTACTACCTGTCTTTAGAGTTCTATATGGGACGGACGCTACAGAACACCATG
GTGAACCTGGCCTTAGAGAATGCCTGTGACGAGGCCACCTACCAGCTGGGCCTGGACATG
GAGGAGCTGGAGGAAATTGAGGAGGATGCGGGGCTGGGCAACGGGGGCCTGGGCCGGCTG
GCAGCCTGCTTTCTTGACTCCATGGCAACACTGGGCCTGGCTGCCTATGGCTACGGGATT
CGCTATGAGTTTGGGATTTTTAACCAGAAGATCTCCGGGGGCTGGCAGATGGAGGAGGCC
GATGACTGGCTTCGCTACGGCAACCCCTGGGAGAAGGCCCGGCCCGAGTTCACGCTACCT
GTGCACTTCTACGGCCATGTGGAGCACACCAGCCAGGGTGCCAAGTGGGTGGACACACAG
GTGGTACTGGCCATGCCCTACGATACCCCGGTGCCTGGCTATCGCAACAATGTTGTCAAC
ACCATGCGCCTCTGGTCTGCCAAGGCTCCCAATGACTTCAACCTCAAGGACTTCAATGTC
GGTGGCTACATCCAGGCTGTGTTGGACCGAAACCTGGCGGAGAACATCTCTCGTGTCCTG
TACCCCAATGATAATTTCTTCGAAGGGAAGGAGCTGCGGCTGAAGCAGGAGTATTTCGTG
GTGGCTGCCACCCTCCAGGACATCATCCGTCGCTTCAAGTCTTCCAAGTTCGGCTGCCGT
GATCCCGTGCGCACGAACTTCGATGCCTTCCCAGATAAGGTGGCCATCCAGCTCAATGAC
ACCCACCCCTCCCTGGCCATCCCCGAGCTGATGAGGATCCTGGTGGACCTGGAACGGATG
GACTGGGACAAGGCGTGGGATGTGACAGTGAGGACCTGTGCCTACACCAACCACACGGTG
CTGCCCGAGGCCCTGGAGCGCTGGCCGGTGCACCTCTTGGAGACGCTGCTGCCGCGGCAC
CTCCAGATCATCTACGAGATCAACCAGCGCTTCCTCAACCGGGTGGCGGCCGCATTCCCA
GGGGACGTAGACCGGCTGCGGCGCATGTCGCTGGTGGAGGAGGGCGCAGTGAAGCGCATC
AACATGGCACACCTGTGCATCGCGGGGTCGCACGCCGTCAACGGTGTGGCCCGCATCCAC
TCGGAGATCCTCAAGAAGACCATCTTCAAAGACTTCTATGAGCTGGAGCCTCATAAGTTC
CAGAATAAGACCAACGGCATCACCCCTCGGCGCTGGCTGGTTCTGTGTAACCCCGGGCTG
GCAGAGGTCATTGCTGAGCGCATCGGGGAGGACTTCATCTCTGACCTGGACCAGCTGCGC
AAACTGCTCTCCTTTGTGGATGATGAAGCTTTCATTCGGGATGTGGCCAAAGTGAAGCAG
GAAAACAAGTTGAAGTTTGCTGCCTACCTAGAGAGGGAATACAAAGTCCACATCAACCCC
AACTCACTCTTCGACATCCAGGTGAAGCGGATTCACGAATATAAACGACAGCTCCTCAAC
TGCCTCCATGTCATCACCCTGTACAACCGCATCAAGAGGGAGCCCAATAAGTTTTTTGTG
CCTCGGACTGTGATGATTGGAGGGAAGGCTGCACCTGGGTACCACATGGCCAAGATGATC
ATCAGACTCGTCACAGCCATCGGGGATGTGGTCAACCATGACCCGGCAGTGGGTGACCGC
CTCCGTGTCATCTTCCTGGAGAACTACCGAGTCTCACTGGCCGAGAAAGTGATCCCAGCT
GCAGACCTCTCTGAGCAGATCTCCACTGCGGGCACTGAAGCCTCAGGCACCGGCAACATG
AAGTTCATGCTCAACGGGGCTCTGACCATTGGCACCATGGACGGGGCCAATGTGGAGATG
GCAGAAGAGGCGGGAGAGGAAAACTTCTTCATCTTTGGCATGCGGGTGGAGGATGTGGAT
AAGCTTGACCAAAGAGGGTACAATGCCCAGGAGTACTACGATCGCATTCCTGAGCTTCGG
CAGGTCATTGAGCAGCTGAGCAGTGGCTTCTTCTCCCCCAAACAACCCGACCTGTTCAAG
GACATTGTCAATATGCTCATGCACCATGACCGGTTTAAAGTCTTCGCAGATTATGAAGAC
TACATTAAATGCCAGGAGAAAGTCAGCGCCTGGTACAAGAACCCAAGAGAGTGGACGCGG
ATGGTGATCCGGAACATAGCCACTTCTGGCAAGTTCTCCAGTGACCGCACCATTGCCCAG
TATGCCCGGGAGATCTGGGGTGTGGAGCCTTCCCGCCAGCGCCTGCCAGCCCCGGATGAG
GCCATCTGA

# Drug_Target_21_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_21_General_References:
10382911	Andreu AL, Bruno C, Tamburino L, Gamez J, Shanske S, Cervera C, Navarro C, DiMauro S: A new mutation in the myophosphorylase gene (Asn684Tyr) in a Spanish patient with McArdle's disease. Neuromuscul Disord. 1999 May;9(3):171-3.
10382912	Rubio JC, Martin MA, Garcia A, Campos Y, Cabello A, Culebras JM, Arenas J: McArdle's disease associated with homozygosity for the missense mutation Gly204Ser of the myophosphorylase gene in a Spanish patient. Neuromuscul Disord. 1999 May;9(3):174-5.
10417800	Gamez J, Fernandez R, Bruno C, Andreu AL, Cervera C, Navarro C, Schwartz S, Dimauro S: A new mutation in the regulatory domain of the myophosphorylase gene affecting protein dimer contact. Muscle Nerve. 1999 Aug;22(8):1136-8.
10590419	Rubio JC, Martin MA, Campos Y, Auciello R, Cabello A, Arenas J: A missense mutation W797R in the myophosphorylase gene in a Spanish patient with McArdle's disease. Muscle Nerve. 2000 Jan;23(1):129-31.
10681080	Fernandez R, Navarro C, Andreu AL, Bruno C, Shanske S, Gamez J, Teijeira S, Hernandez I, Teijeiro A, Fernandez JM, Musumeci O, DiMauro S: A novel missense mutation (W797R) in the myophosphorylase gene in Spanish patients with McArdle disease. Arch Neurol. 2000 Feb;57(2):217-9.
10714589	Rubio JC, Martin MA, Campos Y, Cabello A, Arenas J: A missense mutation T487N in the myophosphorylase gene in a Spanish patient with McArdle's disease. Neuromuscul Disord. 2000 Feb;10(2):138-40.
10899452	Martin MA, Rubio JC, Campos Y, Ricoy JR, Cabello A, Arenas J: A homozygous missense mutation (A659D) in the myophosphorylase gene in a Spanish patient with McArdle's disease. Neuromuscul Disord. 2000 Aug;10(6):447-9.
11706962	Martin MA, Rubio JC, Buchbinder J, Fernandez-Hojas R, del Hoyo P, Teijeira S, Gamez J, Navarro C, Fernandez JM, Cabello A, Campos Y, Cervera C, Culebras JM, Andreu AL, Fletterick R, Arenas J: Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study. Ann Neurol. 2001 Nov;50(5):574-81.
12031624	Bruno C, Lanzillo R, Biedi C, Iadicicco L, Minetti C, Santoro L: Two new mutations in the myophosphorylase gene in Italian patients with McArdle's disease. Neuromuscul Disord. 2002 Jun;12(5):498-500.
3447177	Burke J, Hwang P, Anderson L, Lebo R, Gorin F, Fletterick R: Intron/exon structure of the human gene for the muscle isozyme of glycogen phosphorylase. Proteins. 1987;2(3):177-87.
3466902	Gautron S, Daegelen D, Mennecier F, Dubocq D, Kahn A, Dreyfus JC: Molecular mechanisms of McArdle's disease (muscle glycogen phosphorylase deficiency). RNA and DNA analysis. J Clin Invest. 1987 Jan;79(1):275-81.
3840433	Hwang PK, See YP, Vincentini AM, Powers MA, Fletterick RJ, Crerar MM: Comparative sequence analysis of rat, rabbit, and human muscle glycogen phosphorylase cDNAs. Eur J Biochem. 1985 Oct 15;152(2):267-74.
7603523	Tsujino S, Shanske S, Nonaka I, DiMauro S: The molecular genetic basis of myophosphorylase deficiency (McArdle's disease). Muscle Nerve. 1995;3:S23-7.
8316268	Tsujino S, Shanske S, DiMauro S: Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease). N Engl J Med. 1993 Jul 22;329(4):241-5.
8535454	Tsujino S, Shanske S, Martinuzzi A, Heiman-Patterson T, DiMauro S: Two novel missense mutations (E654K, L396P) in Caucasian patients with myophosphorylase deficiency (McArdle's disease). Hum Mutat. 1995;6(3):276-7.
9506549	Vorgerd M, Kubisch C, Burwinkel B, Reichmann H, Mortier W, Tettenborn B, Pongratz D, Lindemuth R, Tegenthoff M, Malin JP, Kilimann MW: Mutation analysis in myophosphorylase deficiency (McArdle's disease). Ann Neurol. 1998 Mar;43(3):326-31.

# Drug_Target_21_HGNC_ID:
HGNC:9726

# Drug_Target_21_HPRD_ID:
01986

# Drug_Target_21_ID:
1152

# Drug_Target_21_Locus:
11q12-q13.2

# Drug_Target_21_Molecular_Weight:
97093

# Drug_Target_21_Name:
Glycogen phosphorylase, muscle form

# Drug_Target_21_Number_of_Residues:
842

# Drug_Target_21_PDB_ID:
1XL1

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00343	Phosphorylase

# Drug_Target_21_Protein_Sequence:
>Glycogen phosphorylase, muscle form
MSRPLSDQEKRKQISVRGLAGVENVTELKKNFNRHLHFTLVKDRNVATPRDYYFALAHTV
RDHLVGRWIRTQQHYYEKDPKRIYYLSLEFYMGRTLQNTMVNLALENACDEATYQLGLDM
EELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKISGGWQMEEA
DDWLRYGNPWEKARPEFTLPVHFYGHVEHTSQGAKWVDTQVVLAMPYDTPVPGYRNNVVN
TMRLWSAKAPNDFNLKDFNVGGYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFV
VAATLQDIIRRFKSSKFGCRDPVRTNFDAFPDKVAIQLNDTHPSLAIPELMRILVDLERM
DWDKAWDVTVRTCAYTNHTVLPEALERWPVHLLETLLPRHLQIIYEINQRFLNRVAAAFP
GDVDRLRRMSLVEEGAVKRINMAHLCIAGSHAVNGVARIHSEILKKTIFKDFYELEPHKF
QNKTNGITPRRWLVLCNPGLAEVIAERIGEDFISDLDQLRKLLSFVDDEAFIRDVAKVKQ
ENKLKFAAYLEREYKVHINPNSLFDIQVKRIHEYKRQLLNCLHVITLYNRIKREPNKFFV
PRTVMIGGKAAPGYHMAKMIIRLVTAIGDVVNHDPAVGDRLRVIFLENYRVSLAEKVIPA
ADLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENFFIFGMRVEDVD
KLDQRGYNAQEYYDRIPELRQVIEQLSSGFFSPKQPDLFKDIVNMLMHHDRFKVFADYED
YIKCQEKVSALYKNPREWTRMVIRNIATSGKFSSDRTIAQYAREIWGVEPSRQRLPAPDE
AI

# Drug_Target_21_Reaction:
(1,4-alpha-D-glucosyl)n + phosphate = (1,4-alpha-D-glucosyl)n-1 + alpha-D-glucose 1-phosphate

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties

# Drug_Target_21_SwissProt_ID:
P11217

# Drug_Target_21_SwissProt_Name:
PYGM_HUMAN

# Drug_Target_21_Synonyms:
EC 2.4.1.1
Myophosphorylase

# Drug_Target_21_Theoretical_pI:
7.03

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
L47359

# Drug_Target_2_GenBank_ID_Protein:
2529269

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
spoIIAA

# Drug_Target_2_Gene_Sequence:
>354 bp
ATGCATTTTCAATTAGAAATGGTCACAAGAGAGACAGTCGTTATACGTTTATTTGGGGAG
CTCGATCATCATGCAGTAGAGCAAATTCGAGCGAAAATTTCTGCAGCAATTTTCCAAGGC
ACTGTGACGACCATCATTTGGAACTTAGAAGGGCTATCTTTTATGGATAGTTCGGGAGTA
GGTTTAGTGCTTGGTCGTATGCGTGAGTTAGAGGCAGTTGCTGGGCGAACTATTTTATTG
AATCCATCGCCAACCATGCGAAAAGTTTTTCAATTTTCAGGTTTAGGGCCTTGGATGATG
GATGCAACAGAGGAACAAGCGATTGATCGCGTAAGGGGGATTGTAAATGGATAA

# Drug_Target_2_General_Function:
Signal transduction mechanisms

# Drug_Target_2_General_References:
11470435	Seavers PR, Lewis RJ, Brannigan JA, Verschueren KH, Murshudov GN, Wilkinson AJ: Structure of the Bacillus cell fate determinant SpoIIAA in phosphorylated and unphosphorylated forms. Structure. 2001 Jul 3;9(7):605-14.
9266669	Park SG, Yudkin MD: Sequencing and phylogenetic analysis of the spoIIA operon from diverse Bacillus and Paenibacillus species. Gene. 1997 Jul 18;194(1):25-33.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3602

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
13043

# Drug_Target_2_Name:
Anti-sigma F factor antagonist

# Drug_Target_2_Number_of_Residues:
117

# Drug_Target_2_PDB_ID:
1H4Z

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01740	STAS

# Drug_Target_2_Protein_Sequence:
>Anti-sigma F factor antagonist
MHFQLEMVTRETVVIRLFGELDHHAVEQIRAKISAAIFQGTVTTIIWNLEGLSFMDSSGV
GLVLGRMRELEAVAGRTILLNPSPTMRKVFQFSGLGPWMMDATEEQAIDRVRGIVNG

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
In the phosphorylated form it could act as an anti-anti- sigma factor that counteracts spoIIAB and thus releases sigma f from inhibition

# Drug_Target_2_SwissProt_ID:
O32723

# Drug_Target_2_SwissProt_Name:
SP2AA_BACSH

# Drug_Target_2_Synonyms:
Stage II sporulation protein AA

# Drug_Target_2_Theoretical_pI:
6.25

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
K02078

# Drug_Target_3_GenBank_ID_Protein:
150288

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
pilE1

# Drug_Target_3_Gene_Sequence:
>501 bp
ATGAATACCCTTCAAAAAGGCTTTACCCTTATCGAGCTGATGATTGTGATCGCTATCGTC
GGCATTTTGGCGGCAGTCGCCCTTCCCGCCTACCAAGACTACACCGCCCGCGCGCAAGTT
TCCGAAGCCATCCTTTTGGCCGAAGGTCAAAAATCAGCCGTCACCGAGTATTACCTGAAT
CACGGCAAATGGCCGGAAAACAACACTTCTGCCGGCGTGGCATCCCCCCCCTCCGACATC
AAAGGCAAATATGTTAAAGAGGTTGAAGTTAAAAACGGCGTCGTTACCGCCACAATGCTT
TCAAGCGGCGTAAACAATGAAATCAAAGGCAAAAAACTCTCCCTGTGGGCCAGGCGTGAA
AACGGTTCGGTAAAATGGTTCTGCGGACAGCCGGTTACGCGCACCGACGACGACACCGTT
GCCGACGCCAAAGACGGCAAAGAAATCGACACCAAGCACCTGCCGTCAACCTGCCGCGAT
AAGGCATCTGATGCCAAATGA

# Drug_Target_3_General_Function:
Cell motility

# Drug_Target_3_General_References:
10048019	Forest KT, Dunham SA, Koomey M, Tainer JA: Crystallographic structure reveals phosphorylated pilin from Neisseria: phosphoserine sites modify type IV pilus surface chemistry and fibre morphology. Mol Microbiol. 1999 Feb;31(3):743-52.
1348857	Jonsson AB, Pfeifer J, Normark S: Neisseria gonorrhoeae PilC expression provides a selective mechanism for structural diversity of pili. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3204-8.
1671354	Jonsson AB, Nyberg G, Normark S: Phase variation of gonococcal pili by frameshift mutation in pilC, a novel gene for pilus assembly. EMBO J. 1991 Feb;10(2):477-88.
2872674	Bergstrom S, Robbins K, Koomey JM, Swanson J: Piliation control mechanisms in Neisseria gonorrhoeae. Proc Natl Acad Sci U S A. 1986 Jun;83(11):3890-4.
6143785	Schoolnik GK, Fernandez R, Tai JY, Rothbard J, Gotschlich EC: Gonococcal pili. Primary structure and receptor binding domain. J Exp Med. 1984 May 1;159(5):1351-70.
6148752	Meyer TF, Billyard E, Haas R, Storzbach S, So M: Pilus genes of Neisseria gonorrheae: chromosomal organization and DNA sequence. Proc Natl Acad Sci U S A. 1984 Oct;81(19):6110-4.
7477282	Parge HE, Forest KT, Hickey MJ, Christensen DA, Getzoff ED, Tainer JA: Structure of the fibre-forming protein pilin at 2.6 A resolution. Nature. 1995 Nov 2;378(6552):32-8.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3119

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
17945

# Drug_Target_3_Name:
Fimbrial protein

# Drug_Target_3_Number_of_Residues:
165

# Drug_Target_3_PDB_ID:
1AY2

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00114	Pilin
PF07963	N_methyl

# Drug_Target_3_Protein_Sequence:
>Fimbrial protein precursor
MNTLQKGFTLIELMIVIAIVGILAAVALPAYQDYTARAQVSEAILLAEGQKSAVTEYYLN
HGKWPENNTSAGVASPPSDIKGKYVKEVEVKNGVVTATMLSSGVNNEIKGKKLSLWARRE
NGSVKWFCGQPVTRTDDDTVADAKDGKEIDTKHLPSTCRDNFDAK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
This protein is the predominant Neisseria surface antigen, which allows adhesion of the bacterium to various host cells

# Drug_Target_3_SwissProt_ID:
P02974

# Drug_Target_3_SwissProt_Name:
FMM1_NEIGO

# Drug_Target_3_Synonyms:
Fimbrial protein precursor
MS11 antigen
Pilin

# Drug_Target_3_Theoretical_pI:
7.40

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Periplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
X04586

# Drug_Target_4_GenBank_ID_Protein:
581187

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
phoA

# Drug_Target_4_Gene_Sequence:
>1416 bp
GTGAAACAAAGCACTATTGCACTGGCACTCTTACCGTTACTGTTTACCCCTGTGACAAAA
GCCCGGACACCAGAAATGCCTGTTCTGGAAAACCGGGCTGCTCAGGGCGATATTACTGCA
CCCGGCGGTGCTCGCCGTTTAACGGGTGATCAGACTGCCGCTCTGCGTGATTCTCTTAGC
GATAAACCTGCAAAAAATATTATTTTGCTGATTGGCGATGGGATGGGGGACTCGGAAATT
ACTGCCGCACGTAATTATGCCGAAGGTGCGGGCGGCTTTTTTAAAGGTATAGATGCCTTA
CCGCTTACCGGGCAATACACTCACTATGCGCTGAATAAAAAAACCGGCAAACCGGACTAC
GTCACCGACTCGGCTGCATCAGCAACCGCCTGGTCAACCGGTGTCAAAACCTATAACGGC
GCGCTGGGCGTCGATATTCACGAAAAAGATCACCCAACGATTCTGGAAATGGCAAAAGCC
GCAGGTCTGGCGACCGGTAACGTTTCTACCGCAGAGTTGCAGGATGCCACGCCCGCTGCG
CTGGTGGCACATGTGACCTCGCGCAAATGCTACGGTCCGAGCGCGACCAGTGAAAAATGT
CCGGGTAACGCTCTGGAAAAAGGCGGAAAAGGATCGATTACCGAACAGCTGCTTAACGCT
CGTGCCGACGTTACGCTTGGCGGCGGCGCAAAAACCTTTGCTGAAACGGCAACCGCTGGT
GAATGGCAGGGAAAAACGCTGCGTGAACAGGCACAGGCGCGTGGTTATCAGTTGGTGAGC
GATGCTGCCTCACTGAATTCGGTGACGGAAGCGAATCAGCAAAAACCCCTGCTTGGCCTG
TTTGCTGACGGCAATATGCCAGTGCGCTGGCTAGGACCGAAAGCAACGTACCATGGCAAT
ATCGATAAGCCCGCAGTCACCTGTACGCCAAATCCGCAACGTAATGACAGTGTACCAACC
CTGGCGCAGATGACCGACAAAGCCATTGAATTGTTGAGTAAAAATGAGAAAGGCTTTTTC
CTGCAAGTTGAAGGTGCGTCAATCGATAAACAGGATCATGCTGCGAATCCTTGTGGGCAA
ATTGGCGAGACGGTCGATCTCGATGAAGCCGTACAACGGGCGCTGGAATTCGCTAAAAAG
GAGGGTAACACGCTGGTCATAGTCACCGCTGATCACGCCCACGCCAGCCAGATTGTTGCG
CCGGATACCAAAGCTCCGGGCCTCACCCAGGCGCTAAATACCAAAGATGGCGCAGTGATG
GTGATGAGTTACGGGAACTCCGAAGAGGATTCACAAGAACATACCGGCAGTCAGTTGCGT
ATTGCGGCGTATGGCCCGCATGCCGCCAATGTTGTTGGACTGACCGACCAGACCGATCTC
TTCTACACCATGAAAGCCGCTCTGGGGCTGAAATAA

# Drug_Target_4_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_4_General_References:
10085061	Holtz KM, Stec B, Kantrowitz ER: A model of the transition state in the alkaline phosphatase reaction. J Biol Chem. 1999 Mar 26;274(13):8351-4.
2010919	Kim EE, Wyckoff HW: Reaction mechanism of alkaline phosphatase based on crystal structures. Two-metal ion catalysis. J Mol Biol. 1991 Mar 20;218(2):449-64.
2345142	Agrawal DK, Wanner BL: A phoA structural gene mutation that conditionally affects formation of the enzyme bacterial alkaline phosphatase. J Bacteriol. 1990 Jun;172(6):3180-90.
2668291	Laforet GA, Kaiser ET, Kendall DA: Signal peptide subsegments are not always functionally interchangeable. M13 procoat hydrophobic core fails to transport alkaline phosphatase in Escherichia coli. J Biol Chem. 1989 Aug 25;264(24):14478-85.
3045828	DuBose RF, Dykhuizen DE, Hartl DL: Genetic exchange among natural isolates of bacteria: recombination within the phoA gene of Escherichia coli. Proc Natl Acad Sci U S A. 1988 Sep;85(18):7036-40.
3522543	Michaelis S, Hunt JF, Beckwith J: Effects of signal sequence mutations on the kinetics of alkaline phosphatase export to the periplasm in Escherichia coli. J Bacteriol. 1986 Jul;167(1):160-7.
3533724	Chang CN, Kuang WJ, Chen EY: Nucleotide sequence of the alkaline phosphatase gene of Escherichia coli. Gene. 1986;44(1):121-5.
3537962	Shuttleworth H, Taylor J, Minton N: Sequence of the gene for alkaline phosphatase from Escherichia coli JM83. Nucleic Acids Res. 1986 Nov 11;14(21):8689.
3910843	Sowadski JM, Handschumacher MD, Murthy HM, Foster BA, Wyckoff HW: Refined structure of alkaline phosphatase from Escherichia coli at 2.8 A resolution. J Mol Biol. 1985 Nov 20;186(2):417-33.
3912261	Gray GL, Baldridge JS, McKeown KS, Heyneker HL, Chang CN: Periplasmic production of correctly processed human growth hormone in Escherichia coli: natural and bacterial signal sequences are interchangeable. Gene. 1985;39(2-3):247-54.
6273802	Kikuchi Y, Yoda K, Yamasaki M, Tamura G: The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) of Escherichia coli. Nucleic Acids Res. 1981 Nov 11;9(21):5671-8.
7022451	Bradshaw RA, Cancedda F, Ericsson LH, Neumann PA, Piccoli SP, Schlesinger MJ, Shriefer K, Walsh KA: Amino acid sequence of Escherichia coli alkaline phosphatase. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3473-7.
7035431	Inouye H, Barnes W, Beckwith J: Signal sequence of alkaline phosphatase of Escherichia coli. J Bacteriol. 1982 Feb;149(2):434-9.
8652582	Ma L, Kantrowitz ER: Kinetic and X-ray structural studies of a mutant Escherichia coli alkaline phosphatase (His-412-->Gln) at one of the zinc binding sites. Biochemistry. 1996 Feb 20;35(7):2394-402.
9253408	Murphy JE, Stec B, Ma L, Kantrowitz ER: Trapping and visualization of a covalent enzyme-phosphate intermediate. Nat Struct Biol. 1997 Aug;4(8):618-22.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9533886	Stec B, Hehir MJ, Brennan C, Nolte M, Kantrowitz ER: Kinetic and X-ray structural studies of three mutant E. coli alkaline phosphatases: insights into the catalytic mechanism without the nucleophile Ser102. J Mol Biol. 1998 Apr 3;277(3):647-62.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3453

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
49439

# Drug_Target_4_Name:
Alkaline phosphatase

# Drug_Target_4_Number_of_Residues:
471

# Drug_Target_4_PDB_ID:
1EW9

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00245	Alk_phosphatase

# Drug_Target_4_Protein_Sequence:
>Alkaline phosphatase precursor
MKQSTIALALLPLLFTPVTKARTPEMPVLENRAAQGDITAPGGARRLTGDQTAALRDSLS
DKPAKNIILLIGDGMGDSEITAARNYAEGAGGFFKGIDALPLTGQYTHYALNKKTGKPDY
VTDSAASATAWSTGVKTYNGALGVDIHEKDHPTILEMAKAAGLATGNVSTAELQDATPAA
LVAHVTSRKCYGPSATSEKCPGNALEKGGKGSITEQLLNARADVTLGGGAKTFAETATAG
EWQGKTLREQAQARGYQLVSDAASLNSVTEANQQKPLLGLFADGNMPVRWLGPKATYHGN
IDKPAVTCTPNPQRNDSVPTLAQMTDKAIELLSKNEKGFFLQVEGASIDKQDHAANPCGQ
IGETVDLDEAVQRALEFAKKEGNTLVIVTADHAHASQIVAPDTKAPGLTQALNTKDGAVM
VMSYGNSEEDSQEHTGSQLRIAAYGPHAANVVGLTDQTDLFYTMKAALGLK

# Drug_Target_4_Reaction:
a phosphate monoester + H2O = an alcohol + phosphate

# Drug_Target_4_Signals:
1-21

# Drug_Target_4_Specific_Function:
A phosphate monoester + H(2)O = an alcohol + phosphate

# Drug_Target_4_SwissProt_ID:
P00634

# Drug_Target_4_SwissProt_Name:
PPB_ECOLI

# Drug_Target_4_Synonyms:
APase
Alkaline phosphatase precursor
EC 3.1.3.1

# Drug_Target_4_Theoretical_pI:
6.02

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
Not Available

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
SERPINB3

# Drug_Target_5_Gene_Sequence:
Not Available

# Drug_Target_5_General_Function:
Not Available

# Drug_Target_5_General_References:
Not Available

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
6973

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
Not Available

# Drug_Target_5_Name:
Serpin B3

# Drug_Target_5_Number_of_Residues:
0

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
Not Available

# Drug_Target_5_Protein_Sequence:
Not Available

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
Not Available

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
P29508

# Drug_Target_5_SwissProt_Name:
SPB3_HUMAN

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
Not Available

# Drug_Target_5_Transmembrane_Regions:
Not Available

# Drug_Target_6_Cellular_Location:
Cytoplasmic

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
X83269

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
xynY

# Drug_Target_6_Gene_Sequence:
>3234 bp
ATGAAAAACAAGAGAGTTTTGGCAAAAATAACGGCTCTTGTGGTATTGCTGGGAGTGTTT
TTTGTATTACCGTCAAACATAAGTCAGCTATATGCTGATTATGAAGTGGTTCATGACACT
TTTGAAGTTAACTTTGACGGATGGTGTAACTTGGGAGTCGACACATATTTAACGGCAGTT
GAAAATGAAGGAAACAACGGTACAAGAGGTATGATGGTAATAAATCGCTCCAGTGCGAGT
GACGGTGCGTATTCGGAAAAAGGTTTCTATCTCGACGGTGGTGTAGAATACAAGTACAGT
GTTTTTGTAAAACACAACGGGACCGGCACCGAAACTTTCAAACTTTCTGTGTCCTATTTG
GATTCGGAAACAGAAGAAGAAAATAAGGAAGTAATTGCAACAAAGGATGTTGTGGCCGGA
GAATGGACTGAGATTTCGGCAAAATACAAAGCACCCAAAACTGCAGTGAATATTACTTTG
TCAATTACAACCGACAGCACTGTAGATTTCATTTTTGACGATGTAACCATAACCCGTAAA
GGAATGGCTGAGGCAAACACAGTATATGCAGCAAACGCTGTGCTGAAAGATATGTATGCA
AACTATTTCAGAGTTGGTTCGGTACTTAACTCCGGAACGGTAAACAATTCATCAATAAAG
GCCTTGATTTTAAGAGAGTTTAACAGTATTACCTGTGAAAATGAAATGAAGCCTGATGCC
ACACTGGTTCAATCAGGATCAACCAATACAAATATCAGGGTTTCTCTTAATCGTGCAGCA
AGTATTTTAAACTTCTGTGCACAAAATAATATAGCCGTCAGAGGTCATACACTGGTTTGG
CACAGCCAGACACCTCAATGGTTTTTCAAAGACAATTTCCAGGACAACGGAAACTGGGTT
TCCCAATCAGTTATGGACCAGCGTTTGGAAAGCTACATAAAAAATATGTTTGCTGAAATC
CAAAGACAGTATCCGTCTTTGAATCTTTATGCCTATGACGTTGTAAATGAGGCAGTAAGT
GATGATGCAAACAGGACCAGATATTATGGCGGGGCGAGGGAACCTGGATACGGAAATGGT
AGATCTCCATGGGTTCAGATCTACGGAGACAACAAATTTATTGAGAAAGCATTTACATAT
GCAAGAAAATATGCTCCGGCAAATTGTAAGCTTTACTACAACGATTACAACGAATATTGG
GATCATAAGAGAGACTGTATTGCCTCAATTTGTGCAAACTTGTACAACAAGGGCTTGCTT
GACGGTGTGGGAATGCAGTCCCATATTAATGCGGATATGAATGGATTCTCAGGTATACAA
AATTATAAAGCAGCTTTGCAGAAATATATAAATATCGGTTGTGATGTCCAAATTACCGAG
CTTGATATTAGTACAGAAAACGGCAAATTTAGCTTACAGCAGCAGGCTGATAAATATAAA
GCTGTTTTCCAGGCAGCTGTTGATATAAACAGAACCTCCAGCAAAGGAAAGGTTACGGCT
GTCTGTGTATGGGGACCTAATGACGCCAATACTTGGCTCGGTTCACAAAATGCACCTCTT
TTGTTTAACGCAAACAATCAACCGAAACCGGCATACAATGCGGTTGCATCCATTATTCCT
CAGTCCGAATGGGGCGACGGTAACAATCCGGCCGGCGGCGGAGGAGGAGGCAAACCGGAA
GAGCCGGATGCAAACGGATATTATTATCATGACACTTTTGAAGGAAGCGTAGGACAGTGG
ACAGCCAGAGGACCTGCGGAAGTTCTGCTTAGCGGAAGAACGGCTTACAAAGGTTCAGAA
TCACTCTTGGTAAGGAACCGTACGGCAGCATGGAACGGAGCACAACGGGCGCTGAATCCC
AGAACGTTTGTTCCCGGAAACACATATTGTTTCAGCGTAGTGGCATCGTTTATTGAAGGT
GCGTCTTCCACAACATTCTGCATGAAGCTGCAATACGTAGACGGAAGCGGCACTCAACGG
TATGATACCATAGATATGAAAACTGTGGGTCCAAATCAGTGGGTTCACCTGTACAATCCG
CAATACAGAATTCCTTCCGATGCAACAGATATGTATGTTTATGTGGAAACAGCGGATGAC
ACCATTAACTTCTACATAGATGAGGCAATCGGAGCGGTTGCCGGAACTGTAATCGAAGGA
CCTGCTCCACAGCCTACACAGCCTCCGGTACTGCTTGGCGATGTAAACGGTGATGGAACC
ATTAACTCAACTGACTTGACAATGTTAAAGAGAAGCGTGTTGAGGGCAATCACCCTTACC
GACGATGCAAAGGCTAGAGCAGACGTTGACAAGAATGGATCGATAAACAGCACTGATGTT
TTACTTCTTTCACGCTACCTTTTAAGAGTAATCGACAAATTTCCTGTAGCAGAAAATCCT
TCTTCTTCTTTTAAATATGAGTCGGCCGTGCAATATCGGCCGGCTCCTGATTCTTATTTA
AACCCTTGTCCGCAGGCGGGAAGAATTGTCAAGGAAACATATACAGGAATAAACGGAACT
AAGAGTCTTAATGTATATCTTCCATACGGTTATGATCCGAACAAAAAATATAACATTTTC
TACCTTATGCATGGCGGCGGTGAAAATGAGAATACGATTTTCAGCAACGATGTTAAATTG
CAAAATATCCTTGACCACGCGATTATGAACGGTGAACTTGAGCCTTTGATTGTAGTAACA
CCCACTTTCAACGGCGGAAACTGCACGGCCCAAAACTTTTATCAGGAATTCAGGCAAAAT
GTCATTCCTTTTGTGGAAAGCAAGTACTCTACTTATGCAGAATCAACAACCCCACAGGGA
ATAGCCGCTTCAAGAATGCACAGAGGTTTCGGCGGATTCTCAATGGGAGGATTGACAACA
TGGTATGTAATGGTTAACTGCCTTGATTACGTTGCATATTTTATGCCTTTAAGCGGTGAC
TACTGGTATGGAAACAGTCCGCAGGATAAGGCTAATTCAATTGCTGAAGCAATTAACAGA
TCCGGACTTTCAAAGAGGGAGTATTTCGTATTTGCGGCCACCGGTTCCGACCATATTGCA
TATGCTAATATGAATCCTCAAATTGAAGCTATGAAGGCTTTGCCGCATTTTGATTATACT
TCGGATTTTTCCAAAGGTAATTTTTACTTTCTTGTAGCTCCGGGCGCCACTCACTGGTGG
GGATACGTAAGACATTATATTTATGATGCACTTCCATATTTCTTCCATGAATGA

# Drug_Target_6_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_6_General_References:
7717969	Fontes CM, Hazlewood GP, Morag E, Hall J, Hirst BH, Gilbert HJ: Evidence for a general role for non-catalytic thermostabilizing domains in xylanases from thermophilic bacteria. Biochem J. 1995 Apr 1;307 ( Pt 1):151-8.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
5150

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
119674

# Drug_Target_6_Name:
Endo-1,4-beta-xylanase Y

# Drug_Target_6_Number_of_Residues:
1077

# Drug_Target_6_PDB_ID:
1WB5

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00331	Glyco_hydro_10
PF00404	Dockerin_1
PF00756	Esterase
PF02018	CBM_4_9

# Drug_Target_6_Protein_Sequence:
>Endo-1,4-beta-xylanase Y
MKNKRVLAKITALVVLLGVFFVLPSNISQLYADYEVVHDTFEVNFDGWCNLGVDTYLTAV
ENEGNNGTRGMMVINRSSASDGAYSEKGFYLDGGVEYKYSVFVKHNGTGTETFKLSVSYL
DSETEEENKEVIATKDVVAGEWTEISAKYKAPKTAVNITLSITTDSTVDFIFDDVTITRK
GMAEANTVYAANAVLKDMYANYFRVGSVLNSGTVNNSSIKALILREFNSITCENEMKPDA
TLVQSGSTNTNIRVSLNRAASILNFCAQNNIAVRGHTLVWHSQTPQWFFKDNFQDNGNWV
SQSVMDQRLESYIKNMFAEIQRQYPSLNLYAYDVVNEAVSDDANRTRYYGGAREPGYGNG
RSPWVQIYGDNKFIEKAFTYARKYAPANCKLYYNDYNEYWDHKRDCIASICANLYNKGLL
DGVGMQSHINADMNGFSGIQNYKAALQKYINIGCDVQITELDISTENGKFSLQQQADKYK
AVFQAAVDINRTSSKGKVTAVCVWGPNDANTWLGSQNAPLLFNANNQPKPAYNAVASIIP
QSEWGDGNNPAGGGGGGKPEEPDANGYYYHDTFEGSVGQWTARGPAEVLLSGRTAYKGSE
SLLVRNRTAAWNGAQRALNPRTFVPGNTYCFSVVASFIEGASSTTFCMKLQYVDGSGTQR
YDTIDMKTVGPNQWVHLYNPQYRIPSDATDMYVYVETADDTINFYIDEAIGAVAGTVIEG
PAPQPTQPPVLLGDVNGDGTINSTDLTMLKRSVLRAITLTDDAKARADVDKNGSINSTDV
LLLSRYLLRVIDKFPVAENPSSSFKYESAVQYRPAPDSYLNPCPQAGRIVKETYTGINGT
KSLNVYLPYGYDPNKKYNIFYLMHGGGENENTIFSNDVKLQNILDHAIMNGELEPLIVVT
PTFNGGNCTAQNFYQEFRQNVIPFVESKYSTYAESTTPQGIAASRMHRGFGGFSMGGLTT
WYVMVNCLDYVAYFMPLSGDYWYGNSPQDKANSIAEAINRSGLSKREYFVFAATGSDHIA
YANMNPQIEAMKALPHFDYTSDFSKGNFYFLVAPGATHWWGYVRHYIYDALPYFFHE

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
1-26

# Drug_Target_6_Specific_Function:
Endohydrolysis of 1,4-beta-D-xylosidic linkages in xylans

# Drug_Target_6_SwissProt_ID:
P51584

# Drug_Target_6_SwissProt_Name:
XYNY_CLOTM

# Drug_Target_6_Synonyms:
1,4-beta-D-xylan xylanohydrolase Y
EC 3.2.1.8
Endo-1,4-beta-xylanase Y precursor
XYLY
Xylanase Y

# Drug_Target_6_Theoretical_pI:
5.19

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
RHO

# Drug_Target_7_GenBank_ID_Gene:
U49742

# Drug_Target_7_GenBank_ID_Protein:
1236137

# Drug_Target_7_GeneCard_ID:
RHO

# Drug_Target_7_Gene_Name:
RHO

# Drug_Target_7_Gene_Sequence:
>1047 bp
ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTA
CGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTG
GCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTAC
GTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCC
GTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCAT
GGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGC
GGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGT
AAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACC
TGGGTCATGGCGCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCC
GAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAACAAC
GAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTT
TTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCA
GCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCT
TTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGC
TCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATC
TACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACC
ATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACG
GAGACGAGCCAGGTGGCCCCGGCCTAA

# Drug_Target_7_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_7_General_References:
1302614	Farrar GJ, Findlay JB, Kumar-Singh R, Kenna P, Humphries MM, Sharpe E, Humphries P: Autosomal dominant retinitis pigmentosa: a novel mutation in the rhodopsin gene in the original 3q linked family. Hum Mol Genet. 1992 Dec;1(9):769-71.
1391967	Fujiki K, Hotta Y, Hayakawa M, Sakuma H, Shiono T, Noro M, Sakuma T, Tamai M, Hikiji K, Kawaguchi R, et al.: Point mutations of rhodopsin gene found in Japanese families with autosomal dominant retinitis pigmentosa (ADRP). Jpn J Hum Genet. 1992 Jun;37(2):125-32.
1833777	Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL: Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9370-4.
1840561	Gal A, Artlich A, Ludwig M, Niemeyer G, Olek K, Schwinger E, Schinzel A: Pro-347-Arg mutation of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Genomics. 1991 Oct;11(2):468-70.
1862076	Sung CH, Davenport CM, Hennessey JC, Maumenee IH, Jacobson SG, Heckenlively JR, Nowakowski R, Fishman G, Gouras P, Nathans J: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6481-5.
1897520	Sheffield VC, Fishman GA, Beck JS, Kimura AE, Stone EM: Identification of novel rhodopsin mutations associated with retinitis pigmentosa by GC-clamped denaturing gradient gel electrophoresis. Am J Hum Genet. 1991 Oct;49(4):699-706.
1985460	Inglehearn CF, Bashir R, Lester DH, Jay M, Bird AC, Bhattacharya SS: A 3-bp deletion in the rhodopsin gene in a family with autosomal dominant retinitis pigmentosa. Am J Hum Genet. 1991 Jan;48(1):26-30.
2137202	Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW, Sandberg MA, Berson EL: A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature. 1990 Jan 25;343(6256):364-6.
2215617	Dryja TP, McGee TL, Hahn LB, Cowley GS, Olsson JE, Reichel E, Sandberg MA, Berson EL: Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med. 1990 Nov 8;323(19):1302-7.
2239971	Farrar GJ, Kenna P, Redmond R, McWilliam P, Bradley DG, Humphries MM, Sharp EM, Inglehearn CF, Bashir R, Jay M, et al.: Autosomal dominant retinitis pigmentosa: absence of the rhodopsin proline----histidine substitution (codon 23) in pedigrees from Europe. Am J Hum Genet. 1990 Dec;47(6):941-5.
6589631	Nathans J, Hogness DS: Isolation and nucleotide sequence of the gene encoding human rhodopsin. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4851-5.
7633434	Macke JP, Hennessey JC, Nathans J: Rhodopsin mutation proline347-to-alanine in a family with autosomal dominant retinitis pigmentosa indicates an important role for proline at position 347. Hum Mol Genet. 1995 Apr;4(4):775-6.
7846071	Sieving PA, Richards JE, Naarendorp F, Bingham EL, Scott K, Alpern M: Dark-light: model for nightblindness from the human rhodopsin Gly-90-->Asp mutation. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):880-4.
7981701	Fuchs S, Kranich H, Denton MJ, Zrenner E, Bhattacharya SS, Humphries P, Gal A: Three novel rhodopsin mutations (C110F, L131P, A164V) in patients with autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Jul;3(7):1203.
7987326	Antinolo G, Sanchez B, Borrego S, Rueda T, Chaparro P, Cabeza JC: Identification of a new mutation at codon 171 of rhodopsin gene causing autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1421.
7987331	Souied E, Gerber S, Rozet JM, Bonneau D, Dufier JL, Ghazi I, Philip N, Soubrane G, Coscas G, Munnich A, et al.: Five novel missense mutations of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1433-4.
7987385	Kumaramanickavel G, Maw M, Denton MJ, John S, Srikumari CR, Orth U, Oehlmann R, Gal A: Missense rhodopsin mutation in a family with recessive RP. Nat Genet. 1994 Sep;8(1):10-1.
8045708	Rosas DJ, Roman AJ, Weissbrod P, Macke JP, Nathans J: Autosomal dominant retinitis pigmentosa in a large family: a clinical and molecular genetic study. Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3134-44.
8076945	Reig C, Antich J, Gean E, Garcia-Sandoval B, Ramos C, Ayuso C, Carballo M: Identification of a novel rhodopsin mutation (Met-44-Thr) in a simplex case of retinitis pigmentosa. Hum Genet. 1994 Sep;94(3):283-6.
8081400	al-Maghtheh M, Inglehearn C, Lunt P, Jay M, Bird A, Bhattacharya S: Two new rhodopsin transversion mutations (L40R; M216K) in families with autosomal dominant retinitis pigmentosa. Hum Mutat. 1994;3(4):409-10.
8088850	Vaithinathan R, Berson EL, Dryja TP: Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. Genomics. 1994 May 15;21(2):461-3.
8317502	Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, Conway BP, Heckenlively J, Palmer R, Maumenee IH, Sieving P, et al.: Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet. 1993 Jul;53(1):80-9.
8353500	Kranich H, Bartkowski S, Denton MJ, Krey S, Dickinson P, Duvigneau C, Gal A: Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet. 1993 Jun;2(6):813-4.
8358437	Dryja TP, Berson EL, Rao VR, Oprian DD: Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet. 1993 Jul;4(3):280-3.
8401533	al-Maghtheh M, Gregory C, Inglehearn C, Hardcastle A, Bhattacharya S: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Hum Mutat. 1993;2(4):249-55.
8554077	Souied E, Soubrane G, Benlian P, Coscas GJ, Gerber S, Munnich A, Kaplan J: Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. Am J Ophthalmol. 1996 Jan;121(1):19-25.
9452035	Goliath R, Bardien S, September A, Martin R, Ramesar R, Greenberg J: Rhodopsin mutation G109R in a family with autosomal dominant retinitis pigmentosa. Hum Mutat. 1998;Suppl 1:S40-1.
9888392	al-Jandal N, Farrar GJ, Kiang AS, Humphries MM, Bannon N, Findlay JB, Humphries P, Kenna PF: A novel mutation within the rhodopsin gene (Thr-94-Ile) causing autosomal dominant congenital stationary night blindness. Hum Mutat. 1999;13(1):75-81.

# Drug_Target_7_HGNC_ID:
HGNC:10012

# Drug_Target_7_HPRD_ID:
01584

# Drug_Target_7_ID:
2207

# Drug_Target_7_Locus:
3q21-q24

# Drug_Target_7_Molecular_Weight:
38893

# Drug_Target_7_Name:
Rhodopsin

# Drug_Target_7_Number_of_Residues:
348

# Drug_Target_7_PDB_ID:
1LN6

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_7_Protein_Sequence:
>Rhodopsin
MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLY
VTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLG
GEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIP
EGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQES
ATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAI
YNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Visual pigments are the light-absorbing molecules that mediate vision. They consist of an apoprotein, opsin, covalently linked to cis-retinal

# Drug_Target_7_SwissProt_ID:
P08100

# Drug_Target_7_SwissProt_Name:
OPSD_HUMAN

# Drug_Target_7_Synonyms:
Opsin-2

# Drug_Target_7_Theoretical_pI:
6.64

# Drug_Target_7_Transmembrane_Regions:
37-61
74-98
114-133
153-176
203-230
253-276
285-309

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
Not Available

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
TAOK2

# Drug_Target_8_Gene_Sequence:
Not Available

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
Not Available

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
7142

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
Not Available

# Drug_Target_8_Name:
Serine/threonine-protein kinase TAO2

# Drug_Target_8_Number_of_Residues:
0

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
Not Available

# Drug_Target_8_Protein_Sequence:
Not Available

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
Not Available

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
Q9UL54

# Drug_Target_8_SwissProt_Name:
TAOK2_HUMAN

# Drug_Target_8_Synonyms:
Not Available

# Drug_Target_8_Theoretical_pI:
Not Available

# Drug_Target_8_Transmembrane_Regions:
Not Available

# Drug_Target_9_Cellular_Location:
Membrane

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
Not Available

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
KCNC4

# Drug_Target_9_GenBank_ID_Gene:
AL137790

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
KCNC4

# Drug_Target_9_Gene_Sequence:
>1908 bp
ATGATCAGCTCGGTGTGTGTCTCCTCCTACCGCGGGCGCAAGTCGGGGAACAAGCCTCCG
TCCAAAACATGTCTGAAGGAGGAGATGGCCAAGGGCGAGGCGTCGGAGAAGATCATCATC
AACGTGGGCGGCACGCGACATGAGACCTACCGCAGCACCCTGCGCACCCTACCGGGAACC
CGCCTCGCCTGGCTGGCCGACCCCGACGGCGGGGGCCGGCCCGAGACCGATGGCGGCGGT
GTGGGTAGCAGCGGCAGCAGCGGCGGCGGGGGCTGCGAGTTCTTCTTCGACAGGCACCCG
GGCGTCTTCGCCTACGTGCTCAACTACTACCGCACCGGCAAGCTGCACTGCCCCGCGGAC
GTGTGCGGGCCGCTCTTCGAAGAGGAGCTCACCTTCTGGGGCATCGACGAGACCGACGTG
GAACCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTCGACATC
TTCGAGAGCCCGGACGGAGGCGGCAGCGGCGCGGGGCCCAGCGACGAGGCCGGCGACGAT
GAGCGGGAGCTGGCCCTGCAGCGACTGGGCCCCCACGAGGGAGGCGCGGGCCATGGCGCC
GGGTCTGGGGGCTGCCGCGGCTGGCAGCCCCGCATGTGGGCGCTCTTCGAGGATCCCTAC
TCCTCCCGGGCCGCTAGGGTAGTGGCCTTTGCCTCTCTCTTCTTCATCCTGGTCTCCATC
ACCACTTTCTGCCTGGAGACCCATGAGGCCTTTAATATCGACCGCAACGTGACAGAGATC
CTCCGCGTAGGGAACATCACCAGCGTGCACTTCCGGCGGGAGGTAGAGACAGAGCCCATC
CTGACCTACATCGAGGGCGTATGTGTGCTGTGGTTCACACTGGAGTTCCTGGTGCGCATC
GTGTGCTGCCCCGACACGCTGGACTTCGTCAAGAACCTGCTCAACATCATCGACTTTGTG
GCCATCCTGCCCTTCTACCTGGAGGTGGGGCTGAGCGGCCTGTCATCCAAGGCGGCCCGC
GACGTGCTGGGCTTCCTGCGCGTGGTGCGCTTCGTGCGCATCCTGCGTATCTTCAAGCTC
ACACGCCACTTCGTGGGGCTACGCGTGCTGGGCCACACCCTGAGGGCCAGCACCAATGAG
TTCCTGCTGCTTATCATCTTCCTGGCCCTGGGTGTGCTCATCTTTGCCACCATGATCTAC
TACGCTGAGCGCATTGGGGCCAGGCCCTCCGACCCTCGGGGTAATGACCACACCGACTTC
AAGAACATCCCCATTGGCTTCTGGTGGGCTGTGGTCACCATGACGACACTGGGCTACGGA
GACATGTACCCCAAGACGTGGTCAGGCATGCTGGTAGGGGCACTGTGTGCACTGGCTGGC
GTGCTCACCATCGCCATGCCGGTGCCTGTCATCGTCAACAACTTCGGCATGTACTACTCC
CTGGCCATGGCCAAGCAGAAGCTGCCCAAGAAACGGAAGAAGCACGTGCCACGGCCGGCG
CAGCTGGAGTCACCCATGTACTGCAAGTCTGAGGAGACTTCCCCCCGGGACAGCACCTGC
AGTGATACCAGCCCCCCTGCCCGGGAAGAGGGTATGATCGAGAGGAAACGGGCAGACTCT
AAGCAGAATGGCGATGCCAACGCAGTGCTGTCTGATGAGGAGGGAGCTGGCCTCACCCAA
CCCCTGGCCTCCTCCCCGACCCCCGAGGAGCGCCGGGCCCTGCGACGCTCCACCACTCGA
GACAGAAACAAGAAGGCAGCTGCCTGCTTCCTGCTCAGCACTGGGGACTATGCCTGCGCC
GATGGTAGTGTCCGGAAAGGCACATTCGTCCTCCGTGACCTTCCCCTTCAGCATTCACCT
GAGGCTGCATGCCCTCCAACTGCTGGGACTCTGTTCCTGCCACATTGA

# Drug_Target_9_General_Function:
Involved in protein binding

# Drug_Target_9_General_References:
1381835	Vega-Saenz de Miera E, Moreno H, Fruhling D, Kentros C, Rudy B: Cloning of ShIII (Shaw-like) cDNAs encoding a novel high-voltage-activating, TEA-sensitive, type-A K+ channel. Proc Biol Sci. 1992 Apr 22;248(1321):9-18.

# Drug_Target_9_HGNC_ID:
HGNC:6236

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
5686

# Drug_Target_9_Locus:
1p21

# Drug_Target_9_Molecular_Weight:
69767

# Drug_Target_9_Name:
Potassium voltage-gated channel subfamily C member 4

# Drug_Target_9_Number_of_Residues:
635

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00520	Ion_trans
PF02214	K_tetra

# Drug_Target_9_Protein_Sequence:
>Potassium voltage-gated channel subfamily C member 4
MISSVCVSSYRGRKSGNKPPSKTCLKEEMAKGEASEKIIINVGGTRHETYRSTLRTLPGT
RLAWLADPDGGGRPETDGGGVGSSGSSGGGGCEFFFDRHPGVFAYVLNYYRTGKLHCPAD
VCGPLFEEELTFWGIDETDVEPCCWMTYRQHRDAEEALDIFESPDGGGSGAGPSDEAGDD
ERELALQRLGPHEGGAGHGAGSGGCRGWQPRMWALFEDPYSSRAARVVAFASLFFILVSI
TTFCLETHEAFNIDRNVTEILRVGNITSVHFRREVETEPILTYIEGVCVLWFTLEFLVRI
VCCPDTLDFVKNLLNIIDFVAILPFYLEVGLSGLSSKAARDVLGFLRVVRFVRILRIFKL
TRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGARPSDPRGNDHTDF
KNIPIGFWWAVVTMTTLGYGDMYPKTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYS
LAMAKQKLPKKRKKHVPRPAQLESPMYCKSEETSPRDSTCSDTSPPAREEGMIERKRADS
KQNGDANAVLSDEEGAGLTQPLASSPTPEERRALRRSTTRDRNKKAAACFLLSTGDYACA
DGSVRKGTFVLRDLPLQHSPEAACPPTAGTLFLPH

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
This protein mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient

# Drug_Target_9_SwissProt_ID:
Q03721

# Drug_Target_9_SwissProt_Name:
KCNC4_HUMAN

# Drug_Target_9_Synonyms:
KSHIIIC
Voltage-gated potassium channel subunit Kv3.4

# Drug_Target_9_Theoretical_pI:
6.98

# Drug_Target_9_Transmembrane_Regions:
227-247
278-298
313-333
345-364
381-401
452-472

#END_DRUGCARD DB04522
